WO1998002536A2 - Preparation of pichia methanolica auxotrophic mutants - Google Patents

Preparation of pichia methanolica auxotrophic mutants Download PDF

Info

Publication number
WO1998002536A2
WO1998002536A2 PCT/US1997/012582 US9712582W WO9802536A2 WO 1998002536 A2 WO1998002536 A2 WO 1998002536A2 US 9712582 W US9712582 W US 9712582W WO 9802536 A2 WO9802536 A2 WO 9802536A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
dna
methanolica
ade
culturing
Prior art date
Application number
PCT/US1997/012582
Other languages
French (fr)
Other versions
WO1998002536A3 (en
Inventor
Christopher K. Raymond
Original Assignee
Zymogenetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/703,808 external-priority patent/US5736383A/en
Application filed by Zymogenetics, Inc. filed Critical Zymogenetics, Inc.
Priority to EP97936103A priority Critical patent/EP0946734B1/en
Priority to DE69735369T priority patent/DE69735369T2/en
Priority to JP50632398A priority patent/JP2002514049A/en
Priority to IL12807297A priority patent/IL128072A0/en
Priority to CA002261020A priority patent/CA2261020C/en
Priority to AU38856/97A priority patent/AU708572B2/en
Publication of WO1998002536A2 publication Critical patent/WO1998002536A2/en
Publication of WO1998002536A3 publication Critical patent/WO1998002536A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces

Definitions

  • Methyiotrophic yeasts are those yeasts that are able to utilize methanol as a sole source of carbon and energy. Species of yeasts that have the biochemical pathways necessary for methanol utilization are classified in four genera. Hansenula. Pichia. Candida, and Torulopsis These genera are somewhat artificial, having been based on cell and growth characteristics, and do not reflect close genetic relationships (Billon-Grand. Mvcotaxon .35.201-204, 1989; Kurtzman, Mvcologia 84.7 * 2-76. 1992). Furthermore, not all species within these genera are capable of utilizing methanol as a source of carbon and energ ⁇ As a consequence of this classification, there are great differences in physiology and metabolism between individual species of a genus
  • Methyiotrophic yeasts are attractive candidates for use in recombinant protein production systems. Some methyiotrophic yeasts have been shown to grow rapidh to high biomass on minimal defined media Certain genes of methyiotrophic yeasts are tightly regulated and highh expressed under induced or de-repressed conditions, suggesting that promoters of these genes might be useful for producing polypeptides of commercial value See. for example. Faber et al.. Yeast 11:1331. 1 95; Romanos et al.. Yeast 8:423. 1992; and Cregg et al.. Bio/Technoiog ⁇ 1 1 905. 1993
  • methyiotrophic yeasts as hosts for use in recombinant production systems has been slow, due in part to a lack of suitable materials (e.g., promoters, selectable markers, and mutant host cells) and methods (e.g.. transformation techniques)
  • suitable materials e.g., promoters, selectable markers, and mutant host cells
  • methods e.g.. transformation techniques
  • the most highh developed methyiotrophic host systems utilize Pichia pastor is and Hansenula p ⁇ lvmorpha (Faber et al., Curr Genet. 25:305- 310, 1994; Cregg et al.. ibid.: Romanos et al. ibid..
  • the present invention provides methods for preparing Pichia methanolica cells having an auxotrophic mutation.
  • the methods comprise the steps of (a) exposing P methanolica cells to mutagenizing conditions: (b) culturing the cells from step (a) in a rich medium to allow mutations to become established and replicated in at least a portion of the cells, (c ) culturing the cells from step (b) in a culture medium deficient in assimilable nitrogen to deplete celluiar nitrogen stores: (d) culturing the cells from step (c) in a defined culture medium comprising an inorganic nitrogen source and an amount of nystatin sufficient to kill growing P methanolica cells to select for cells having a deficiency in a nutritional gene, and (e) culturing the selected cells trom step (d) in a rich culture medium
  • the selected cells trom step (ei are replica plated to a defined medium and cultured to confirm the presence of an auxotroph
  • Fig 1 illustrates the effects of field strength androue duration on electroporation efficient of P methanolica
  • Fig 2 is a schematic diagram of a recombination event between plasmid pCZR140 and P methanolica genomic DNA
  • Fig 3 is a schematic diagram of a recombination event between plasmid pCZR137 and P methanolica genomic DNA
  • a "DNA construct” is a DNA molecule, either single- or double-stranded, that has been modified through human intervention to contain segments of DNA combined and luxtaposed m an arrangement not existing in nature
  • “Earh log phase growth” is that phase of cellular growth in culture when the cell concentration is from 2 x 10° cells/ml to 8 x 10 ⁇ cells/ml
  • Heterologous DNA refers to a DNA molecule, or a population of DN A molecules, that does not exist naturally within a given host cell
  • DNA molecules heterologous to a particular host cell may contain DNA derived from the host cell species so long as that host DNA is combined with non-host DNA
  • a DNA molecule containing a non-host DNA segment encoding a polypeptide operably linked to a host DNA segment comprising a transcription promoter is considered to be a heterologous DNA molecule
  • a "higher eukaryotic" organism is a multicellular eukaryotic organism The term encompasses both plants and animals
  • Linear DNA denotes DNA molecules having free 5 and 3 ends that is non- circular DNA molecules
  • Linear DNA can be prepared from closed circular DNA molecules, such as plasmids. by enzvmatic digestion or physical disruption
  • the term "operably linked" indicates that DNA segments are arranged so that they function in concert for their intended purposes, e.g.. transcription initiates in the promoter and proceeds through the coding segment to the terminator.
  • promoter is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commoniy, but not always, found in the 5' non-coding regions of genes. Sequence elements within promoters that function in the initiation of transcription are often characterized by consensus nucleotide sequences. These promoter elements include RNA polymerase binding sites; TATA sequences: CAAT sequences: differentiation-specific elements (DSEs; McGehee et al., Mol. Endocrinol.
  • CREs cyclic AMP response elements
  • SREs serum response elements
  • GREs glucocorticoid response elements
  • binding sites for other transcription factors such as CRE/ATF
  • a “repressing carbon source” is a metabolizable. carbon-containing compound that, when not limited, suppresses the expression in an organism of genes required for the catablism of other carbon sources.
  • limited is meant that the carbon source is unavailable or becomes available at such a rate that it is immediately consumed and therefore the prevailing concentration of that carbon source in an organism ' s environment is effectively zero.
  • Repressing carbon sources that can be used within the present invention include hexoses and ethanol. Glucose is particularly preferred.
  • “Rich " culture media are those culture media that are based on complex sources of nutrients, typically cell or tissue extracts or protein hydrolysates. Rich media will vary in composition from batch to batch due to variations in the composition of the nutrient sources.
  • the present invention provides methods for preparing Pichia methanolica cells having an auxotrophic mutation.
  • Auxotrophic mutants of P. methanolica can be transformed with both homologous DNA (DNA from the host species) and heterologous DNA, and the resulting transformants can be used within a large number of diverse biological applications.
  • the mutant cells of the present invention are particularly well suited for transformation with heterologous DNA.
  • which transformed cells can be used for the production of polypeptides and proteins, including polypeptides and proteins of higher organisms, including humans.
  • Auxotrophic P. methanolica cells can be transformed with other DNA molecules, including DNA libraries and synthetic DNA molecules.
  • the invention thus provides host cells that can be used to express genetically diverse libraries to produce products that are screened for novel biological activities, can be engineered for use as targets for the screening of compound libraries, and can be genetically modified to enhance their utility within other processes.
  • Cells to be transformed with heterologous DNA will commonly have a mutation that can be complemented by a gene (a "selectable marker") on the heterologous DNA molecule.
  • This selectable marker allows the transformed cells to grow under conditions in which untransformed cells cannot multiply ("selective conditions")
  • selectable conditions The general principles ot selection are well known in the an Commonly used selectable markers are genes that encode enzymes required for the synthesis of ammo acids or nucleotides Cells having mutations in these genes (auxotrophic mutants) cannot grow in media lacking the specific ammo acid or nucleotide unless the mutation is complemented by the selectable marker Use of such "selective" culture media ensures the stable maintenance of the heterologous DNA within the host cell
  • a preferred selectable marker of this type for use in Pichia methanolica is a P methanolica ADE2 gene, which encodes phospho ⁇ bosyl- 5-ammo ⁇ m ⁇ dazole carboxylase (AIRC.
  • the ADE2 gene when transformed into an ade2 host cell, allows the cell to grow in the absence of adenine
  • the coding strand of a representative P methanolica ADE2 gene sequence is shown in SEQ ID NO 1
  • the sequence illustrated includes 1006 nucleotides of 5' non-coding sequence and 442 nucleotides of 3' non- coding sequence, with the initiation ATG codon at nucleotides 1007-1009
  • a DNA segment comprising nucleotides 407-2851 is used as a selectable marker, although longer or shorter segments could be used as long as the coding portion is operabh linked to promoter and terminator sequences
  • this and other sequences provided herein represent single alleles of the respective genes, and that allehc va ⁇ ation is expected to exist Any functional ADE2 allele can be used within the present invention
  • Other nutritional markers that can be used within the present invention include the P methanolica ADE HIS3.
  • Heterologous genes such as genes from other fungi, can also be used as selectable markers. For large-scale, industrial processes where it is desirable to minimize the use of methanol.
  • host cells in which both methanol utilization genes (AUG1 and AUG2) are deleted
  • host cells deficient in vacuolar protease genes PEP4 and PRB1
  • Gene-deficient mutants can be prepared by known methods, such as site-directed mutagenesis P methanolica genes can be cloned on the basis of homology with their counterpart Saccharomyces cerevisiae genes
  • the ADE2 gene disclosed herein was given its designation on the basis of such homology
  • Strains of Pichia methanolica are available from the American Type Culture Collection (Rockville. MD) and other repositories, and can be used as starting matenals within the present invention
  • mutagenizing conditions i.e environmental conditions that cause genetic mutations in the cells
  • Methods for mutagenizing ceils are well known in the art and include chemical treatment, exposure to ultraviolet light, exposure to x-rays, and retroviral insertional mutagenesis
  • Chemical mutagens include ethylmethane sulfonate (EMS). ⁇ -methyl-N-n ⁇ tro- ⁇ -n ⁇ trosoguan ⁇ d ⁇ ne.
  • Balancing is generally done empirically by exposing cells to different conditions to establish a killing curve In general, the cells are exposed to mutagenizing conditions and cultured for one day. after which they are tested for viability according to standard assay methods Within the present invention, it is preferred to use a level of mutagenesis that results in 20-50% mortahtv . although one skilled in the art will recognize that this value can be adjusted as necessary, for example if working with a very large number of cells.
  • Mutagemzed cells are then cultured in a rich medium to allow mutations to become established and replicated in at least a portion of the cell population. This step allows cells in which the genome has been altered to replicate the mutation and pass it on to their progeny, thereby establishing the mutation within the population
  • the cells are then transferred to a culture medium deficient in assimilable nitrogen so that cellular nitrogen stores are depleted.
  • deficient in assimilable nitrogen it is meant that the medium lacks an amount of nitrogen sufficient to support growth of the cells Depletion of cellular nitrogen stores will generally require about 12 to 24 hours of incubation, with 16 hours being sufficient under common conditions
  • the cells are cultured in a defined culture medium comprising an inorganic nitrogen source and an amount of an antifungal antibiotic sufficient to kill growing P methanolica cells
  • a preferred antibiotic is nystatin (mycostatin)
  • Preferred inorganic nitrogen sources are those comprising ammonium ions, such as ammonium sulfate.
  • the medium will contain 10-200 mM ammonium, preferably about 60 mM ammonium Nystatin is included at a concentration of 0.1 to 100 mg/1, preferably 0.5 to 20 mg/L, more preferably about 2 mg/L (10 units/L). Treatment with nystatin is carried out for ten minutes to six hours, preferably about 1 hour.
  • concentration and exposure time required to kill prototrophic cells can be readih determined empirically, and certain adjustments may be necessary to compensate for variations in specific activity between individual batches of antibiotic.
  • Heterologous DNA can be introduced into P methanolica cells by any of several known methods, including lithium transformation (Hiep et al.. Yeast 9 1 189-1 197. 1993: Tarutma and Tolstorukov. Abst of the 15th International Specialized Symposium on Yeasts. Riga (USSR). 1991. 137. Ito et al . J. Bactenol. 153: 163. 1983; Bogdanova et al. Yeast 1 1 :343. 1995). spheroplast transformation (Beggs. Nature 275.: 104. 1978. Hmnen et al, Proc. Natl. Acad. Sci USA 75:1929. 1978: Cregg et al.. Mol Cell. Biol. 5:3376. 1985), freeze-thaw polyethylene glycol transformation
  • Electroporation is the process of using a pulsed electric field to transiently permeabilize cell membranes, allowing macromolecules. such as DNA. to pass into cells. Electroporation has been described for use with mammalian (e.g., Neumann et al.. EMBO J. 1 :841-845. 1982) and fungal (e.g.. Meilhoc et al.. Bio/Technology 8:223- 227. 1990) host cells. However, the actual mechanism by which DNA is transferred into the cells is not well understood. For transformation of P. methanolica.
  • electroporation is surprisingly efficient when the cells are exposed to an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm and a time constant ( ⁇ ) of from 1 to 40 milliseconds.
  • the time constant ⁇ is defined as the time required for the initial peak voltage V 0 to drop to a value of V 0 /e.
  • resistance and capacitance are either preset or may be selected by the user, depending on the electroporation equipment selected. In any event, the equipment is configured in accordance with the manufacturer's instructions to provide field strength and decay parameters as disclosed above. Electroporation equipment is available from commercial suppliers (e.g., BioRad Laboratories. Hercules. CA).
  • DNA molecules for use in transforming P. methanolica will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation.
  • the DNA molecules will include, in addition to the selectable marker disclosed above, an expression casette comprising a transcription promoter, a DNA segment (e.g., a cDN A) encoding the polypeptide or protein of interest, and a transcription terminator. These elements are operably linked to provide for transcription of the DNA segment of interest. It is preferred that the promoter and terminator be that of a P. methanolica gene.
  • Useful promoters include those from constitutive and methanol-inducible promoters.
  • Promoter sequences are generally contained within 1.5 kb upstream of the coding sequence of a gene, often within 1 kb or less. In general, regulated promoters are larger than constitutive promoters due the presence of regulatory elements. Methanol-inducible promoters, which include both positive and negative regulatory elements, may extend more than 1 kb upstream from the initiation ATG. Promoters are identified by function and can be cloned according to known methods.
  • a particularly preferred methanol-inducible promoter is that of a P. methanolica alcohol utilization gene.
  • a representative coding strand sequence of one such gene AUG1. is shown in SEQ ID NO:2. Within SEQ ID NO:2. the initiation ATG codon is at nucleotides 1355- 1357. Nucleotides 1-23 of SEQ ID NO:2 are non-AUGl polylinker sequence. It is particularly preferred to utilize as a promoter a segment comprising nucleotides 24-1354 of SEQ ID NO:2, although additional upstream sequence can be included.
  • P. methanolica contains a second alcohol utilization gene. A UG2. the promoter of which can be used within the present invention.
  • AUG2 promoter segments used within the present invention will generally comprise nucleotides 91-169 of SEQ ID NO:9. although small truncations at the 3 ' end would not be expected to negate promoter function.
  • Other useful promoters include those of the dihydroxyacetone synthase (DHAS). formate dehydrogenase (FMD). and catalase (CAT) genes. Genes encoding these enzymes from other species have been described. and their sequences are available (e.g... Janowicz et al.. Nuc. Acids Res. 11:2043. 1985: Hollenberg and Janowicz.
  • Constitutive promoters are those that are not activated or inactivated b ⁇ environmental conditions, they are always transc ⁇ ptionallv active
  • Preferred constitutive promoters for use within the present invention include those from glyceraldehyde-3-phosphate dehvdrogenase. t ⁇ ose phosphate isomerase.
  • the DNA molecules will further include a selectable marker to allow for identification, selection, and maintenance of transformants
  • the DNA molecules may further contain additional elements, such an origin of replication and a selectable marker that allow amplification and maintenance of the DNA in an alternate host (e g , £ coli)
  • an alternate host e g , £ coli
  • the expression segment will be flanked by cleavage sites to allow for linearization of the molecule and separation of the expression segment from other sequences (e g , a bacterial origin of replication and selectable marker)
  • Preferred such cleavage sites are those that are recognized by restriction endonucleases that cut infrequently within a DNA se ⁇ uence. such as those that recognize 8-base target sequences (e . Not I
  • Proteins that can be produced in P methanolica include proteins ot industrial and pharmaceutical interest Such proteins include higher eukaryotic proteins from plants and animals, particularly vertebrate animals such as mammals, although certain proteins from microorganisms are also of great value Proteins that can be prepared using methods of the present invention include enzvmes such as Upases, cellulases, and proteases, enzyme inhibitors, including protease inhibitors, growth factors such as platelet derived growth factor, fibroblast growth factors, and epidermal growth factor, cytokines such as erythropoietin and thrombopoietm. and hormones such as insulin, leptin. and glucagon
  • P methanolica cells are cultured in a medium comp ⁇ sing adequate sources of carbon, nitrogen and trace nutrients at a temperature of about 25°C to 35°C Liquid cultures are provided with sufficient aeration by conventional means, such as shaking ol small flasks or sparging of fermentors
  • a preferred culture medium is YEPD (Table 1)
  • the cells av be passaged by dilution into fresh culture medium or stored for snort periods on plates under refrigeration For long-term storage, the cells are preferablv kept in a 50% glvcerol solution at -70°C
  • Electroporation of P methanolica is preferably carried out on cells in early log phase growth
  • Cells are streaked to single colonies on solid media, preferably solid YEPD
  • single colonies from a fresh plate are used to inoculate the desired volume of rich culture media (e g , YEPD) to a cell density of about 5 - 10 x 10 3 cells/ml
  • Cells are incubated at about 25 - 35°C. preferably 30°C. with vigorous shaking, until thev are in earh log phase
  • the cells are then harvested, such as by cent ⁇ fugation at 3000 x g for 2-3 minutes, and resuspended Cells are made electrocompetent by reducing disulfide bonds in the cell walls.
  • Cells are typically made electrocompetent by incubating them in a buffered solution at pH 6-8 containing a reducing agent, such as dithiothreitol (DTT) or ⁇ -mercaptoethanol (BME). to reduce cell wall proteins to facilitate subsequent uptake of DNA
  • a reducing agent such as dithiothreitol (DTT) or ⁇ -mercaptoethanol (BME).
  • DTT dithiothreitol
  • BME ⁇ -mercaptoethanol
  • Suitable buffers include pH 6-8 solutions containing a weak buffer, divalent cations (e . Mg Ca ""1" ) and an osmotic stabilizer (e.g .
  • a preferred electroporation buffer is STM (270 mM sucrose, 10 mM
  • the cells are subjected to two washes first in the o ⁇ gmal culture volume of ice-cold buffer, then in one-half the o ⁇ ginal volume Following the second wash, the cells are harvested and resuspended typically using about 3-5 ml of buffer for an original culture volume of 200 ml
  • Electroporation is earned out using a small volume of electrocompetent cells (typically about 100 ⁇ l) and up to one-tenth volume of linear DNA molecules
  • a small volume of electrocompetent cells typically about 100 ⁇ l
  • electrocompetent cells typically about 100 ⁇ l
  • 0 1 ml of cell suspension in a buffer not exceeding 50 mM in ionic strength is combined with 0 1-10 ⁇ g of DNA (vol ⁇ 10 ⁇ l)
  • This mixture is placed in an ice-cold electroporation cuvette and subjected to a pulsed electric field of from 2 5 to 4 5 kV/cm, preferably about 3 75 kV/cm.
  • the cells are then harvested and plated on selective media within a preferred embodiment, the cells are washed once with a small volume (equal to the diluted volume of the electroporated cells) of IX yeast nitrogen base (6 7 g/L yeast nitrogen base without ammo acids, Difco Laboratories. Detroit, MI), and plated on minimal selective media
  • IX yeast nitrogen base (6 7 g/L yeast nitrogen base without ammo acids, Difco Laboratories. Detroit, MI)
  • Cells having an ade2 mutation that have been transformed with an ADE2 selectable marker can be plated on a minimal medium that lacks adenine.
  • ADE D Table 1
  • ADE DS Table 1
  • 250 ⁇ l aliqouts of cells are plated on 4 separate ADE D or ADE DS plates to select for Ade + cells
  • ARS autonomously replicating sequences
  • integrative transformants are generally preferred for use in protein production systems Integrative transformants have a profound growth advantage over ARS transformants on selective media containing sorbitol as a carbon source, thereby providing a method for selecting integrative transformants from among a population of transformed cells ARS sequences have been found to exist in the ADE2 gene and. possibly, the
  • a UG1 gene of P methanolica ade2 host cells of Pichia methanolica transformed with an ADE2 gene can thus become Ade + by at least two different modes
  • the ARS within the ADE2 gene allows unstable extrachromosomal maintenance of the transforming DNA (Hiep et al .
  • Integrative transformants are preferred for use in protein production processes
  • Such cells can be propagated without continuous selective pressure because DNA is rareh lost from the genome Integration of DNA into the host chromosome can be confirmed Southern blot analysis Briefly, transformed and untransformed host DNA is digested with rest ⁇ ction endonuc leases, separated by electrophoresis, blotted to a support membrane, and probed with approp ⁇ ate host DNA segments Differences in the patterns of fragments seen in untransformed and transformed cells are indicative of integrative transformation Restriction enz ⁇ mes and probes can be selected to identify transforming DNA segments (e g . promoter terminator heterologous DNA. and selectable marker sequences) from among the genomic fragments
  • transforming DNA segments e g . promoter terminator heterologous DNA. and selectable marker sequences
  • P methanolica transformants that carry an expression cassette comp ⁇ sing a methanol-regulated promoter (such as the AUGl promoter) are grown in the presence of methanol and the absence of mterfenng amounts of other carbon sources (e g , glucose)
  • transformants may be grown at 30°C on solid media containing, for example. 20 g/L Bacto-agar (Difco). 6 7 g/L yeast nitrogen base without am o acids (Difco). 10 g/L methanol, 0 4 ⁇ g/L biotin.
  • methanol is a volatile carbon source it is readily lost on prolonged incubation
  • a continuous supph of methanol can be provided by placing a solution of 50% methanol in water in the lids of inverted plates, whereby the methanol is transferred to the growing cells bv evaporative transier
  • not more than 1 mL of methanol is used per 100-mm plate
  • Slightlv larger scale expe ⁇ ments can be earned out using cultures grown in shake flasks
  • cells are cultivated for two days on minimal methanol plates as disclosed above at 30°C.
  • colonies are used to inoculate a small volume of minimal methanol media (6 7 g/L veast nitrogen base without amino acids. 10 g/L methanol. 0.4 ⁇ g/L biotin) at a cell density of about 1 x 10 ⁇ cells/ml.
  • minimal methanol media (6 7 g/L veast nitrogen base without amino acids. 10 g/L methanol. 0.4 ⁇ g/L biotin) at a cell density of about 1 x 10 ⁇ cells/ml.
  • Cells are grown at 30°C. Cells growing on methanol have a high oxygen requirement, necessitating vigorous shaking during cultivation. Methanol is replenished daily (typically 1/100 volume of 50% methanol per day).
  • a 500 ml culture in YEPD grown at 30°C for 1-2 days with vigorous agititation is used to inoculate a 5-liter fermenter.
  • the cells are grown in a suitable medium containing salts, glucose, biotin, and trace elements at 28°C, pH 5.0. and >30% dissolved Oi-
  • a glucose/methanol feed is delivered into the vessel to induce production of the protein of interest. Because large-scale fermentation is carried out under conditions of limiting carbon, the presence of glucose in the feed does not repress the methanol-inducible promoter.
  • methanol-inducible gene promoters In a typical fermentation run. a cell density of from about 80 to about 400 grams of wet cell paste per liter is obtained. "Wet cell paste” refers to the mass of cells obtained by harvesting the cells from the fermentor. typically by centrifugation of the culture.
  • P. methanolica cells (strain CBS6515 from American Type Culture Collection.
  • Rockville. MD were mutagenized by UV exposure.
  • a killing curve was first generated by plating cells onto several plates at approximately 200-250 cells/plate. The plates were then exposed to UV radiation using a G8T5 germicidal lamp (Sylvania) suspended 25 cm from the surfaces of the plates for periods of time as shown in Table 2. The plates were then protected from visible light sources and incubated at 30°C for two days.
  • G8T5 germicidal lamp Sylvania
  • the cell suspension was placed in a 2.8 L baffled Bell flask and shaken vigorously at 30°C for 6 hours 50 ml of the culture was set aside in a 250-ml flask as a control, and to the remainder of the culture was added 1 mg nystatin (Sigma Chemical Co . St Louis. MO) to select for auxotrophic mutants (Snow. Nature 211.206-207.
  • nystatin Sigma Chemical Co . St Louis. MO
  • Ade mutants were then subjected to complementation analysis and phenotvpic testing To determine the number of loci defined by the mutants, all 21 mutants were mated to a single pink. Ade" tester strain (strain #2) Mating was earned out by mixing cell suspensions
  • Genomic DNA was prepared from strain CBS6515 according to standard procedures. Briefly, cells were cultured overnight in rich media, spheroplasted with zymolyase. and lysed with SDS. DNA was precipitated from the lysate with ethanol and extracted with a phenol/chloroform mixture, then precipitated with ammonium acetate and ethanol. Gel eiectrophoresis of the DNA preparation showed the presence of intact, high molecular weight DNA and appreciable quantities of RNA. The DNA was partially digested with Sau 3 A by incubating the DNA in the presence of a dilution series of the enzyme. Samples of the digests were analyzed by eiectrophoresis to determine the size distribution of fragments.
  • DNA migrating between 4 and 12 kb was cut from the gel and extracted from the gel slice.
  • the size-fractionated PNA was then ligated to pRS426 that had been digested with Bam HI and treated with alkaline phosphatase. Aliquots of the reaction mixture were electroporated in E. coli MCI 061 cells using a BioRad Gene PulserTM device as recommended by the manufacturer.
  • the genomic library was used to transform S. cerevisiae strain HBY21 A (ade2 ura3) by electroporation (Becker and Guarente. Methods Enzvmol. 194: 182-187. 1991 ).
  • the cells were resuspended in 1.2 M sorbitol, and six 300- ⁇ l aliquots were plated onto ADE D, ADE DS, URA D and URA DS plates (Table 1 ). Plates were incubated at 30°C for 4-5 days. No Ade "1" colonies were recovered on the ADE D or ADE DS plates. Colonies from the URA D and URA DS plates were replica-plated to ADE D plates, and two closely spaced, white colonies were obtained. These colonies were restreaked and confirmed to be Ura "1" and Ade " ⁇ . These two strains, designated Adel and Ade6.
  • Total DNA was isolated from the HBY21A transformants Adel and Ade ⁇ and used to transform E. coli strain MCI 061 to Amp R .
  • DNA was prepared from 2 Amp R colonies of Adel and 3 Amp R colonies of Ade ⁇ . The DNA was digested with Pst I. Sea I, and Pst I + Sea I and analyzed by gel eiectrophoresis. All five isolates produced the same restriction pattern.
  • PCR primers were designed from the published sequence of the P. methanolica ADE2 gene (also known as ADE1 Hiep et al.. Yeast 9:1251-1258. 1993).
  • Primer 9080 (SEQ ID NO:3) was designed to prime at bases 406-429 of the ADE2 DNA (SEQ ID NO:l), and primer 9079 (SEQ ID NO:4) was designed to prime at bases 2852-2829. Both primers included tails to introduce Avr II and Spe I sites at each end of the amplified sequence. The predicted size of the resulting PCR fragment was 2450 bp.
  • PCR was carried out using plasmid DNA from the five putative ADE2 clones as template DNA.
  • the 100 ⁇ l reaction mixtures contained l Taq PCR buffer (Boehringer Mannheim. Indianapolis. IN), 10-100 ng of plasmid DNA. 0.25 mM dNTPs. 100 pmol of each primer, and 1 ⁇ l
  • Taq polymerase Boehringer Mannheim. PCR was run for 30 cycles of 30 seconds at 94°C. 60 seconds at 50°C, and 120 seconds at 72°C. Each of the five putative ADE2 genomic clones yielded a PCR product of the expected size (2.4 kb). Restriction mapping of the DNA fragment from one reaction gave the expected size fragments when digested with Bgl II or Sal I.
  • the positive PCR reactions were pooled and digested with Spe I.
  • Vector pRS426 was digested with Spe I and treated with calf intestinal phosphatase.
  • Four ⁇ l of PCR fragment and 1 ⁇ l of vector DNA were combined in a 10 ⁇ l reaction mix using conventional ligation conditions.
  • the ligated DNA was analyzed by gel eiectrophoresis. Spe I digests were analyzed to identify plasmids carrying a subclone of the ADE2 gene within pRS426.
  • the correct plasmid was designated pCZRl 18. Because the ADE2 gene in pCZR118 had been amplified by PCR, it was possible that mutations that disabled the functional character of the gene could have been generated.
  • the cells were then harvested and resuspended in 200 ml of ice-cold STM (270 mM sucrose, 10 mM Tris, pH 7.5, 1 mM MgCl2). The cells were harvested and resuspended in 100 ml of ice-cold STM. The cells were again harvested and resuspended in 3-5 ml of ice-cold STM. 100- ⁇ l aliquouts of electrocompetent cells from each culture were then mixed with Not I-digested pADEl-1 DNA.
  • the cell/DNA mixture was placed in a 2 mm electroporation cuvette and subjected to a pulsed electric field of 5 kV/cm using a BioRad Gene PulserTM set to 1000 ⁇ resistance and capacitance of 25 ⁇ F. After being pulsed, the cells were diluted by addition of 1 ml YEPD and incubated at 30°C for one hour. The cells were then harvested by gentle centrifugation and resuspended in 400 ⁇ l minimal selective media lacking adenine (ADE D). The resuspended samples were split into 200- ⁇ l aliqouts and plated onto ADE D and ADE DS plates. Plates were incubated at 30°C for 4-5 days. Mutants #6 and #11 gave Ade + transformants. No Ade + transformants were observed when DNA was omitted, hence the two isolates appeared to define the ade2 complementation group.
  • the ADE2 sequence is shown in SEQ ID NO: 1.
  • Example 2 The P. methanolica clone bank disclosed in Example 1 was used as a source for cloning the Alcohol Utilization Gene (AUGl).
  • the clone bank was stored as independent pools. each representing about 200-250 individual genomic clones.
  • 0.1 ⁇ l of "miniprep" DNA from each pool was used as a template in a polymerase chain reaction with PCR primers (8784. SEQ ID NO:5; 8787, SEQ ID NO:6) that were designed from an alignment of conserved sequences in alcohol oxidase genes from Hansenula polymorpha. Candida boidini, and Pichia pastoris.
  • the amplification reaction was run for 30 cycles of 94°C, 30 seconds; 50°C, 30 seconds; 72°C, 60 seconds; followed by a 7 minute incubation at 72°C.
  • One pool (#5) gave a -600 bp band.
  • DNA sequencing of this PCR product revealed that it encoded an amino acid sequence with -70% sequence identity with the Pichia pastoris alcohol oxidase encoded by the AOXl gene and about
  • Sub-pools of pool #5 were analyzed by PCR using the same primers used in the initial amplification. One positive sub-pool was further broken down to identify a positive colony. This positive colony was streaked on plates, and DNA was prepared from individual colonies. Three colonies gave identical patterns after digestion with Cla I.
  • Example 3 ade2 mutant P. methanolica cells are transformed by electroporation essentially as disclosed above with an expression vector comprising the A UG1 promoter and terminator, human GAD65 DNA (Karlsen et al., Proc. Natl. Acad. Sci. USA 88:8337-8341, 1991), and ADE2 selectable marker. Colonies are patched to agar minimal methanol plates ( 10 to 100 colonies per 100-mm plate) containing 20 g/L BactoTM-agar (Difco), 6.7 g/L yeast nitrogen base without amino acids (Difco), 10 g/L methanol, and 0.4 ⁇ g/L biotin.
  • the agar is overlayed with nitrocellulose, and the plates are inverted over lids containing 1 ml of 50% methanol in water and incubated for 3 to 5 days at 30°C.
  • the membrane is then transferred to a filter soaked in 0.2 M NaOH. 0.1% SDS, 35 mM dithiothreitol to lyse the adhered cells.
  • cell debris is rinsed from the filter with distilled water, and the filter is neutralized by rinsing it for 30 minutes in 0.1 M acetic acid.
  • the filters are then assayed for adhered protein. Unoccupied binding sites are blocked by rinsing in TTBS-NFM (20 mM Tris pH 7.4. 0.1% Tween 20, 160 mM NaCl.
  • TTBS-NFM 5% powdered nonfat milk
  • the filters are then transferred to a solution containing GAD6 monoclonal antibody (Chang and Gottlieb. J. Neurosci. 8:2123-2130. 1988), diluted 1:1000 in TTBS-NFM.
  • the filters are incubated in the antibody solution with gentle agitation for at least one hour, then washed with TTBS (20 mM Tris pH 7.4, 0.1%) Tween 20, 160 mM NaCl) two times for five minutes each.
  • TTBS 20 mM Tris pH 7.4, 0.1%) Tween 20, 160 mM NaCl
  • the filters are then incubated in goat anti-mouse antibody conjugated to horseradish peroxidase (1 ⁇ g/ml in TTBS-NFM) for at least one hour, then washed three times, 5 minutes per wash with TTBS.
  • candidate clones are cultured in shake flask cultures. Colonies are grown for two days on minimal methanol plates at 30 °C as disclosed above. The colonies are used to inoculate 20 ml of minimal methanol media (6.7 g/L yeast nitrogen base without amino acids, 10 g/L methanol. 0.4 ⁇ g L biotin) at a cell density of 1 x l ⁇ 6 cells/ml. The cultures are grown for 1-2 days at 30°C with vigorous shaking.
  • 0.2 ml of 50% methanol is added to each culture daily.
  • Cells are harvested by centrifugation and suspended in ice- cold lysis buffer (20 mM Tris pH 8.0, 40 mM NaCl. 2 mM PMSF, 1 mM EDTA, 1 ⁇ g/ml leupeptin. 1 ⁇ g ml pepstatin, 1 ⁇ g/ml aprotinin) at 10 ml final volume per 1 g cell paste.
  • 2.5 ml of the resulting suspension is added to 2.5 ml of 400-600 micron, ice-cold, acid-washed glass beads in a 15-ml vessel, and the mixture is vigorously agitated for one minute, then incubated on ice for 1 minute.
  • the procedure is repeated until the cells have been agitated for a total of five minutes. Large debris and unbroken cells are removed by centrifugation at 1000 x g for 5 minutes. The clarified lysate is then decanted to a clean container. The cleared lysate is diluted in sample buffer (5% SDS, 8 M urea. 100 mM Tris pH 6.8, 10% glycerol, 2 mM EDTA, 0.01% bromphenol glue) and electrophoresed on a 4-20% acrylamide gradient gel (Novex, San Diego, CA). Proteins are blotted to nitrocellose and detected with GAD6 antibody as disclosed above.
  • sample buffer 5% SDS, 8 M urea. 100 mM Tris pH 6.8, 10% glycerol, 2 mM EDTA, 0.01% bromphenol glue
  • Clones exhibiting the highest levels of methanol-induced expression of foreign protein in shake flask culture are more extensively analyzed under high cell density fermentation conditions.
  • Cells are first cultivated in 0.5 liter of YEPD broth at 30°C for 1 - 2 days with vigorous agitation, then used to inoculate a 5-liter fermentation apparatus (e.g., BioFlow III; New Brunswick Scientific Co., Inc.. Edison, NJ).
  • the fermentation vessel is first charged with mineral salts by the addition of 57.8 g (NH 4 ) 2 S0 , 68 g ICH 2 P0 4 , 30.8 g MgS0 4 -7H 2 0.
  • the fermentation vessel is set to run at 28°C, pH 5.0, and >30%> dissolved 0 2 .
  • the cells will consume the initial charge of glucose, as indicated by a shaip demand for oxygen during glucose consumption followed by a decrease in oxygen consumption after glucose is exhausted.
  • a glucose-methanol feed supplemented with NH t * and trace elements is delivered into the vessel at 0.2% (w/v) glucose, 0.2% (w/v) methanol for 5 hours followed by 0.1 %> (w/v) glucose. 0.4% (w/v) methanol for 25 hours.
  • a total of 550 grams of methanol is supplied through one port of the vessel as pure methanol using an initial delivery rate of 12.5 ml/hr and a final rate of 25 ml/hr.
  • Glucose is supplied through a second port using a 700 ml solution containing 175 grams glucose, 250 ml 10X trace elements, and 99 g (NH- ⁇ ) 2 S0 4 . Under these conditions the glucose and methanol are simultaneously utilized, with the induction of GAD65 expression upon commencement of the glucose-methanol feed.
  • Cells from the fermentation vessel are analyzed for GAD55 expression as described above for shake flask cultures.
  • Transformation conditions were investigated to determine the electric field conditions. DNA topology, and DNA concentration that were optimal for efficient transformation of P. methanolica. All experiments used P. methanolica ade2 strain #1 1. Competent cells were prepared as previously described. Electroporation was carried out using a BioRad Gene PulserTM.
  • Field strength is determined by the voltage of the electric pulse, while the pulse duration is determined by the resistance setting of the instrument.
  • the highest capacitance setting (25 ⁇ F) of the instrument was used. 100 ⁇ l aliquots of electrocompetent cells were mixed on ice with 10 ⁇ l of DNA that contained approximately 1 ⁇ g of the ADE2 plasmid pCZR133 that had been linearized with the restriction enzyme Not I.
  • Pulsed cells were suspended in YEPD and incubated at 30°C for one hour, harvested, resuspended. and plated. Three separate sets of experiments were conducted. In each set, electroporation conditions of 0.75 kV (3.75 kV/cm) at a resistance of "infinite" ohms was found to give a dramatically higher transformation efficiency than other conditions tested (see Fig. 1 ).
  • P. methanolica ade2 strain #11 was transformed to Ade + with Asp I-digested pCZR140, a Bluescript® (Stratagene Cloning Systems, La Jolla, CA)-based vector containing the P. methanolica ADE2 gene and a mutant of AUGl in which the entire open reading frame between the promoter and terminator regions has been deleted (Fig. 2).
  • Genomic DNA was prepared from wild- type and transformant cells grown for two days on YEPD plates at 30°C. About 100-200 ⁇ l of cells was suspended in 1 ml H 2 0, then centrifiiged in a microcentrifuge for 30 seconds.
  • the cell pellet was recovered and resuspended in 400 ⁇ l of SCE + DTT + zymolyase (1.2 M sorbitol, 10 mM Na citrate, 10 mM EDTA, 10 mM DTT, 1-2 mg/ml zymolyase 100T) and incubated at 37°C for 10-15 minutes. 400 ⁇ l of 1%> SDS was added, and the solution was mixed until clear. 300 ⁇ l of 5 M potassium acetate, pH 8.9 was added, and the solution was mixed and centrifiiged at top speed in a microcentrifuge for five minutes. 750 ⁇ l of the supernatant was transferred to a new tube and extracted with an equal volume of phenol/chloroform.
  • SCE + DTT + zymolyase 1.2 M sorbitol, 10 mM Na citrate, 10 mM EDTA, 10 mM DTT, 1-2 mg/ml zymolyase 100T
  • DNA was precipitated by the addition of 2 volumes of ethanol and centrifugation for 15 minutes in the cold.
  • the DNA pellet was resuspended in 50 ml TE (10 mM Tris pH 8, 1 mM EDTA) + 100 ⁇ g/ml RNAase for about 1 hour at 65°C. 10- ⁇ l DNA samples were digested with Eco RI (5 ⁇ l) in a 100 ⁇ l reaction volume at 37°C overnight. DNA was precipitated with ethanol. recovered by centrifugation. and resuspended in 7.5 ⁇ l TE + 2.5 ⁇ l 5X loading dye.
  • the entire 10 ml volume was applied to one lane of a 0.7%> agarose in 0.5 X TBE (10 X TBE is 108 g/L Tris base 7-9, 55 g/L boric acid. 8.3 g/L disodium EDTA) gel.
  • the gel was run at 100 V in 0.5 X TBE containing ethidium bromide.
  • the gel was photographed, and DNA was electrophoreticall transferred to a positively derivatized nylon membrane (Nytran® N+, Schleicher & Schuell, Keene, NH) at 400 mA, 20 mV for 30 minutes.
  • the membrane was then rinsed in 2 X SSC. blotted onto denaturation solution for five minutes, neutralized in 2 X SSC.
  • Genomic DNA was prepared as described above from wild-type cells and a stable, white, Ade + transformant and digested with Eco RI. The digested DNA was separated by eiectrophoresis and blotted to a membrane. The blot was probed with a PCR- generated probe corresponding to either the AUGl open reading frame or the A UGl promoter. Results demonstrated that the A UGl open reading frame DNA was absent from the transformant strain, and that the AUGl promoter region had undergone a significant rearrangement. These results are consistent with a double recombination event (transplacement) between the transforming DNA and the host genome (Fig. 3).
  • An AUGl strain of P. methanolica is grown in high-density fermentation conditions.
  • the fermentation vessel is charged with mineral salts by the addition of 57.8 g (NH ) S0 4 , 46.6 g KCl, 30.8 g MgS0 4 -7H 2 0, 8.6 g CaS0 -2H 2 0, 2.0 g NaCl, and 10 ml antifoam (PPG).
  • H 2 0 is added to bring the volume to 2.5 L. and the solution is autoclaved 40 minutes. After cooling. 350 ml of 50% glucose.
  • 210 ml of 30% NaPhosphate, 25 ml 200 ⁇ g/ml biotin, and 250 ml cell inoculum are added.
  • Cells are batch-fed glucose or glucose/methanol in three phases. In phase 1, the cells receive 0.4%/L/hour glucose (w/v final fermentation volume) for 25 hours using 750 g glucose, 1 10 g (NH 4 ) 2 S0 4 , and 278 ml 10 X trace elements per 1.5 liter. The cells are then given a transition feed of 0.2% glucose, 0.2% methanol/L/hour for 5 hours. The final glucose-supplemented methanol feed contains 0.1 % glucose, 0.4% methanol L/hr for 25 hours. Final biomass is about 300 g/L cell paste.
  • the fermentation vessel For fermentation of a P. methanolica augl ⁇ strain, the fermentation vessel is initially charged with mineral salts, glucose, phosphate, trace elements and biotin as disclosed in Example 6. 250 ml of cell inoculum is added. A glucose feed is prepared using 600 g glucose, 108 g (NH 4 ) S0 4 , and 273 ml 10 X trace elements per 1.2 liter. The cells are batch-fed in three phases. In the first phase, the cells receive glucose for 12 to 25 hours at 0.4%/L/hour. The cells are then induced with a bolus addition of 1% methanol by weight and transitioned to methanol utilization with a mixed 0.2% glucose/0.1% methanol feed for 10 hours. In the third phase, a mixed feed of 0.2%) glucose, 0.2%) methanol is delivered for 15 hours.
  • AUG2 P. methanolica cells in which the A UGl gene had been disrupted by insertion of a GAD65 expression construct retained the ability to grow on methanol. indicating that a second alcohol oxidase gene was present.
  • the second gene, designated AUG2 was identified by PCR. Sequence analysis of the 5' coding region of the gene showed that the N-terminus of the encoded protein was similar to those of known alcohol oxidase genes.
  • Strain MC GAD8 a transformant that grew very poorly on minimal methanol broth, was used as a source for cloning the A UG2 gene.
  • Genomic DNA was prepared from MC GAD8 and amplified with sense and antisense PCR primers specific for the AUGl open reading frame (8784, SEQ ID NO:5; 8787, SEQ ID NO:6).
  • a product identical in size to the AUGl product but showing very low intensity on an analytical gel was obtained.
  • the putative A UG2 PCR product was digested with a battery of restriction enzymes. Partial digestion by Eco RI and Pvu I, and the presence of several Bgl II sites suggested that the DNA was contaminated with small amounts of AUGl. To remove the contaminating AUGl DNA, the PCR mixture was cut with Eco RI and gel purified. Since the MC GAD 8 product did not appear to have an Eco RI site, it was unaffected. The resulting gel-purified DNA was reamplified and again analyzed by restriction digestion. The DNA gave a different restriction map from that of the AUGl PCR product.
  • Southern blot analysis was performed on genomic DNA from MC GAD8 and wild- type cells using either AUGl or AUG2 open reading frame PCR fragments as probes.
  • the AUG2 probe hybridized at low stringency to the AUGl locus and at both low and high stringency to a second locus.
  • the A UGl probe bound to both loci at low stringency, but bound predominantly to the AUGl locus at high stringency.
  • PCR primers were designed from the original AUG2 PCR fragment.
  • Primers 9885 SEQ ID NO:7) and 9883 (SEQ ID NO:8) were used to screen a P. methanolica genomic library.
  • a positive clone bank pool was then probed with the original MC GAD8 PCR product.
  • Cells were plated on 10 plates at about 5000 colonies/plate and grown overnight, then the plates were overlayed with filter discs (Hybond-N. Amersham Corp., Arlington Heights. IL). Colonies were denatured, neutralized, and UV cross-linked. Bacterial debris was washed from the filters with 5X SSC. and the filters were again cross-linked. Blots were pre- hybridized in pairs at 42°C for 1 hour in 25 ml hybridization buffer. Approximately 250 ng of probe was then added to each pair of filters. Hybridization was conducted at 42°C for four hours.
  • the blots were then washed in 500 ml of 0.1 X SSC, 6M urea. 0.4% SDS at 42°C for 10 minutes, four times. The blots were then neutralized with 500 ml of 2 X SSC at room temperature for 5 minutes, two rinses. The blots were then immersed in 100 ml development reagent (ECL,
  • Nucleotides upstream from this position are vector sequence.
  • the coding sequence begins at nucleotide 170.
  • Disruption of the AUG2 gene had little effect on cell growth on methanol.
  • Cells lacking both functional AUGl and AUG2 gene products did not grow on methanol.
  • Subsequent analysis showed that the A UGl gene product is the only detectable alcohol oxidase in cells grown in a fermentor.
  • AAAA ⁇ GCTA AAGGAGTACT AGGGCTGTAG TAATAAATAA TGGAACAGTG GTACAACAAT 540
  • MOLECULE TYPE Genomic DNA
  • HYPOTHETICAL NO
  • ANTISENSE NO
  • FRAGMENT TYPE (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
  • GAATTCCTGC AGCCCGGGGG ATCGGGTAGT GGAATGCACG G ⁇ ATACCCA CTCCAAATAA 60
  • AAG ⁇ TTATC TGT ⁇ TTAGA A ⁇ AAAAGAC GA ⁇ G ⁇ GTA ACAAAACG ⁇ GTGCCTACAT 300
  • CAAGACAAAA CAACCCT ⁇ G TCCTGCTC ⁇ ⁇ c ⁇ TCTCA CACCGCGTGG GTGTGTGCGC ' 600
  • AAAG ⁇ TTAT CTCTATGGCC AACGGATAGT CTATCTGC ⁇ AA ⁇ CCATCC ACT ⁇ GGGAA 900
  • CTCCGTGTAC AAGCGGAGCT ⁇ TGCCTCCC ATCCTC ⁇ GC ⁇ TGT ⁇ CGG TTAI 11 III I 1020

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Methods for preparing Pichia methanolica cells having auxotrophic mutations are disclosed. The methods comprise the steps of: (a) exposing P. methanolica cells to mutagenizing conditions; (b) culturing the cells from step (a) in a rich medium to allow mutations to become established and replicated in at least a portion of the cells; (c) culturing the cells from step (b) in a culture medium deficient in assimilable nitrogen to deplete cellular nitrogen stores; (d) culturing the cells from step (c) in a defined culture medium comprising an inorganic nitrogen source and an amount of nystatin sufficient to kill growing P. methanolica cells to select for cells having a deficiency in a nutritional gene; and (e) culturing the selected cells from step (d) in a rich culture medium.

Description

Description PREPARATION OF PICH1A METHANOLICA AUXOTROPHIC MUTANTS
Background of the Invention
Methyiotrophic yeasts are those yeasts that are able to utilize methanol as a sole source of carbon and energy. Species of yeasts that have the biochemical pathways necessary for methanol utilization are classified in four genera. Hansenula. Pichia. Candida, and Torulopsis These genera are somewhat artificial, having been based on cell
Figure imgf000003_0001
and growth characteristics, and do not reflect close genetic relationships (Billon-Grand. Mvcotaxon .35.201-204, 1989; Kurtzman, Mvcologia 84.7*2-76. 1992). Furthermore, not all species within these genera are capable of utilizing methanol as a source of carbon and energ\ As a consequence of this classification, there are great differences in physiology and metabolism between individual species of a genus
Methyiotrophic yeasts are attractive candidates for use in recombinant protein production systems. Some methyiotrophic yeasts have been shown to grow rapidh to high biomass on minimal defined media Certain genes of methyiotrophic yeasts are tightly regulated and highh expressed under induced or de-repressed conditions, suggesting that promoters of these genes might be useful for producing polypeptides of commercial value See. for example. Faber et al.. Yeast 11:1331. 1 95; Romanos et al.. Yeast 8:423. 1992; and Cregg et al.. Bio/Technoiog\ 1 1 905. 1993
Development of methyiotrophic yeasts as hosts for use in recombinant production systems has been slow, due in part to a lack of suitable materials (e.g., promoters, selectable markers, and mutant host cells) and methods (e.g.. transformation techniques) The most highh developed methyiotrophic host systems utilize Pichia pastor is and Hansenula pυlvmorpha (Faber et al., Curr Genet. 25:305- 310, 1994; Cregg et al.. ibid.: Romanos et al. ibid.. U.S Patent No 4.855,242. U.S. Patent No 4,857.467; U.S. Patent No. 4.879.231 : and U.S. Patent No 4.929.555)
There remains a need in the art for methods of transforming additional species of methyiotrophic yeasts and for using the transformed cells to produce polypeptides of economic importance, including industrial enzymes and pharmaceutical proteins The present invention provides compositions and methods useful in these processes as well as other, related advantages.
Summary of the Invention The present invention provides methods for preparing Pichia methanolica cells having an auxotrophic mutation. The methods comprise the steps of (a) exposing P methanolica cells to mutagenizing conditions: (b) culturing the cells from step (a) in a rich medium to allow mutations to become established and replicated in at least a portion of the cells, (c ) culturing the cells from step (b) in a culture medium deficient in assimilable nitrogen to deplete celluiar nitrogen stores: (d) culturing the cells from step (c) in a defined culture medium comprising an inorganic nitrogen source and an amount of nystatin sufficient to kill growing P methanolica cells to select for cells having a deficiency in a nutritional gene, and (e) culturing the selected cells trom step (d) in a rich culture medium Within one embodiment of the invention, the selected cells trom step (ei are replica plated to a defined medium and cultured to confirm the presence of an auxotrophic mutation Within another embodiment, the selected cells are auxotrophic for adenine Within a related embodiment the selected cells are deficient in phosphoπbosyl-5-amιnoιmιdazole carboxylase Within additional embodiments the mutagenizing conditions compnse exposure to ultraviolet light or exposure to a chemical mutagen Within a further embodiment, the inorganic nitrogen source comprises ammonium ions
These and other aspects of the invention will become evident upon relerence to the following detailed descπption and the attached drawings
Brief Description of the Drawings
Fig 1 illustrates the effects of field strength and puise duration on electroporation efficient of P methanolica Fig 2 is a schematic diagram of a recombination event between plasmid pCZR140 and P methanolica genomic DNA
Fig 3 is a schematic diagram of a recombination event between plasmid pCZR137 and P methanolica genomic DNA
Detailed Description of the Invention
Prior to setting forth the invention in more detail, it will be useful to define certain terms used herein
A "DNA construct" is a DNA molecule, either single- or double-stranded, that has been modified through human intervention to contain segments of DNA combined and luxtaposed m an arrangement not existing in nature
"Earh log phase growth" is that phase of cellular growth in culture when the cell concentration is from 2 x 10° cells/ml to 8 x 10^ cells/ml
"Heterologous DNA" refers to a DNA molecule, or a population of DN A molecules, that does not exist naturally within a given host cell DNA molecules heterologous to a particular host cell may contain DNA derived from the host cell species so long as that host DNA is combined with non-host DNA For example, a DNA molecule containing a non-host DNA segment encoding a polypeptide operably linked to a host DNA segment comprising a transcription promoter is considered to be a heterologous DNA molecule
A "higher eukaryotic" organism is a multicellular eukaryotic organism The term encompasses both plants and animals
"'Integrative transformants" are cells into which has been introduced heterologous DNA, wherein the heterologous DNA has become integrated into the genomic DNA of the cells
"Linear DNA" denotes DNA molecules having free 5 and 3 ends that is non- circular DNA molecules Linear DNA can be prepared from closed circular DNA molecules, such as plasmids. by enzvmatic digestion or physical disruption The term "operably linked" indicates that DNA segments are arranged so that they function in concert for their intended purposes, e.g.. transcription initiates in the promoter and proceeds through the coding segment to the terminator.
The term "promoter" is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commoniy, but not always, found in the 5' non-coding regions of genes. Sequence elements within promoters that function in the initiation of transcription are often characterized by consensus nucleotide sequences. These promoter elements include RNA polymerase binding sites; TATA sequences: CAAT sequences: differentiation-specific elements (DSEs; McGehee et al., Mol. Endocrinol. 7:551-560, 1993); cyclic AMP response elements (CREs); serum response elements (SREs; Treisman, Seminars in Cancer Biol. 1:47-58. 1990); glucocorticoid response elements (GREs); and binding sites for other transcription factors, such as CRE/ATF
(O'Reilly et al.. J. Biol. Chem. 267: 19938-19943, 1992), AP2 (Ye et al.. J. Biol. Chem. 269:25728-
25734. 1994), SP1. cAMP response element binding protein (CREB: Loeken. Gene Expr. 3:253- 264. 1993) and octamεr factors. See. in general. Watson et al.. eds.. Molecular Biology of the Gene.
4th ed.. The Benjamin/Cummings Publishing Company. Inc.. Menlo Park. CA. 1987: and Lemaigre and Rousseau, Biochem. J. 303: 1-14, 1994.
A "repressing carbon source" is a metabolizable. carbon-containing compound that, when not limited, suppresses the expression in an organism of genes required for the catablism of other carbon sources. By "limited" is meant that the carbon source is unavailable or becomes available at such a rate that it is immediately consumed and therefore the prevailing concentration of that carbon source in an organism's environment is effectively zero. Repressing carbon sources that can be used within the present invention include hexoses and ethanol. Glucose is particularly preferred. "Rich" culture media are those culture media that are based on complex sources of nutrients, typically cell or tissue extracts or protein hydrolysates. Rich media will vary in composition from batch to batch due to variations in the composition of the nutrient sources.
As noted above, the present invention provides methods for preparing Pichia methanolica cells having an auxotrophic mutation. Auxotrophic mutants of P. methanolica can be transformed with both homologous DNA (DNA from the host species) and heterologous DNA, and the resulting transformants can be used within a large number of diverse biological applications.
The mutant cells of the present invention are particularly well suited for transformation with heterologous DNA. which transformed cells can be used for the production of polypeptides and proteins, including polypeptides and proteins of higher organisms, including humans. Auxotrophic P. methanolica cells can be transformed with other DNA molecules, including DNA libraries and synthetic DNA molecules. The invention thus provides host cells that can be used to express genetically diverse libraries to produce products that are screened for novel biological activities, can be engineered for use as targets for the screening of compound libraries, and can be genetically modified to enhance their utility within other processes. Cells to be transformed with heterologous DNA will commonly have a mutation that can be complemented by a gene (a "selectable marker") on the heterologous DNA molecule. This selectable marker allows the transformed cells to grow under conditions in which untransformed cells cannot multiply ("selective conditions") The general principles ot selection are well known in the an Commonly used selectable markers are genes that encode enzymes required for the synthesis of ammo acids or nucleotides Cells having mutations in these genes (auxotrophic mutants) cannot grow in media lacking the specific ammo acid or nucleotide unless the mutation is complemented by the selectable marker Use of such "selective" culture media ensures the stable maintenance of the heterologous DNA within the host cell A preferred selectable marker of this type for use in Pichia methanolica is a P methanolica ADE2 gene, which encodes phosphoπbosyl- 5-ammoιmιdazole carboxylase (AIRC. EC 4 1.1.21) The ADE2 gene when transformed into an ade2 host cell, allows the cell to grow in the absence of adenine The coding strand of a representative P methanolica ADE2 gene sequence is shown in SEQ ID NO 1 The sequence illustrated includes 1006 nucleotides of 5' non-coding sequence and 442 nucleotides of 3' non- coding sequence, with the initiation ATG codon at nucleotides 1007-1009 Within a preferred embodiment of the invention, a DNA segment comprising nucleotides 407-2851 is used as a selectable marker, although longer or shorter segments could be used as long as the coding portion is operabh linked to promoter and terminator sequences Those skilled in the art will recognize that this and other sequences provided herein represent single alleles of the respective genes, and that allehc vaπation is expected to exist Any functional ADE2 allele can be used within the present invention Other nutritional markers that can be used within the present invention include the P methanolica ADE HIS3. and LEU2 genes, which allow for selection in the absence of adenine. histidine. and leucine. respectively Heterologous genes, such as genes from other fungi, can also be used as selectable markers. For large-scale, industrial processes where it is desirable to minimize the use of methanol. it is preferred to use host cells in which both methanol utilization genes (AUG1 and AUG2) are deleted For production of secreted proteins, host cells deficient in vacuolar protease genes (PEP4 and PRB1) are preferred Gene-deficient mutants can be prepared by known methods, such as site-directed mutagenesis P methanolica genes can be cloned on the basis of homology with their counterpart Saccharomyces cerevisiae genes The ADE2 gene disclosed herein was given its designation on the basis of such homology
Strains of Pichia methanolica are available from the American Type Culture Collection (Rockville. MD) and other repositories, and can be used as starting matenals within the present invention To prepare auxotrophic mutants of P methanolica. cells are first exposed to mutagenizing conditions, i.e environmental conditions that cause genetic mutations in the cells Methods for mutagenizing ceils are well known in the art and include chemical treatment, exposure to ultraviolet light, exposure to x-rays, and retroviral insertional mutagenesis Chemical mutagens include ethylmethane sulfonate (EMS). Λ-methyl-N-nιtro-Λ^-nιtrosoguanιdιne. 2-methoxy-6- chloro-9-[3-(ethyl-2-chloroethyl)amιnopropylamιno]acπdιne2HCl. 5-bromouracιl acπdine. and aflatoxin See Lawrence. Methods Enzvmol 194.273-281. 1991 The proportion or mutagenized cells obtained is a function of the strength or amount of mutagenizing agent to which the cells are exposed A low level of mutagen produces a small proportion of mutant cells Higher levels of mutagen produce a higher proportion ot mutant cells, but also kill more cells It is therefore necessaπ to balance mutagenesis with killing so that a reasonable number of mutant cells is obtained. Balancing is generally done empirically by exposing cells to different conditions to establish a killing curve In general, the cells are exposed to mutagenizing conditions and cultured for one day. after which they are tested for viability according to standard assay methods Within the present invention, it is preferred to use a level of mutagenesis that results in 20-50% mortahtv . although one skilled in the art will recognize that this value can be adjusted as necessary, for example if working with a very large number of cells.
Mutagemzed cells are then cultured in a rich medium to allow mutations to become established and replicated in at least a portion of the cell population. This step allows cells in which the genome has been altered to replicate the mutation and pass it on to their progeny, thereby establishing the mutation within the population
The cells are then transferred to a culture medium deficient in assimilable nitrogen so that cellular nitrogen stores are depleted. By "deficient in assimilable nitrogen" it is meant that the medium lacks an amount of nitrogen sufficient to support growth of the cells Depletion of cellular nitrogen stores will generally require about 12 to 24 hours of incubation, with 16 hours being sufficient under common conditions Following depletion of nitrogen stores, the cells are cultured in a defined culture medium comprising an inorganic nitrogen source and an amount of an antifungal antibiotic sufficient to kill growing P methanolica cells A preferred antibiotic is nystatin (mycostatin) Preferred inorganic nitrogen sources are those comprising ammonium ions, such as ammonium sulfate. In general, the medium will contain 10-200 mM ammonium, preferably about 60 mM ammonium Nystatin is included at a concentration of 0.1 to 100 mg/1, preferably 0.5 to 20 mg/L, more preferably about 2 mg/L (10 units/L). Treatment with nystatin is carried out for ten minutes to six hours, preferably about 1 hour. Those skilled in the art will recognize that the actual antibiotic concentration and exposure time required to kill prototrophic cells can be readih determined empirically, and certain adjustments may be necessary to compensate for variations in specific activity between individual batches of antibiotic. By depleting cellular nitrogen stores and then cultuπng the cells in a defined medium containing an inorganic nitrogen source and antibiotic, cells that are auxotrophic for amino acid or nucleotide biosynthesis remain alive because the\ cannot grow in the defined medium. Growing cells are killed by the antibiotic. Following the antibiotic treatment, the cells are transferred to a rich culture medium. Auxotrophic mutations are confirmed and characterized by determining the nutπent requirements of the treated cells. Replica plating is commonly used for this determination. Cells are plated on both rich medium and media lacking specific nutrients Cells that do not grow on particularly plates are auxotrophic for the missing nutrient. Complementation analysis can be used for further characteπzation. Heterologous DNA can be introduced into P methanolica cells by any of several known methods, including lithium transformation (Hiep et al.. Yeast 9 1 189-1 197. 1993: Tarutma and Tolstorukov. Abst of the 15th International Specialized Symposium on Yeasts. Riga (USSR). 1991. 137. Ito et al . J. Bactenol. 153: 163. 1983; Bogdanova et al. Yeast 1 1 :343. 1995). spheroplast transformation (Beggs. Nature 275.: 104. 1978. Hmnen et al, Proc. Natl. Acad. Sci USA 75:1929. 1978: Cregg et al.. Mol Cell. Biol. 5:3376. 1985), freeze-thaw polyethylene glycol transformation
(Pichia Expression Kit Instruction Manual, Invitrogen Corp.. San Diego. CA. Cat. No. K1710-01 ). or electroporation. the latter method being preferred. Electroporation is the process of using a pulsed electric field to transiently permeabilize cell membranes, allowing macromolecules. such as DNA. to pass into cells. Electroporation has been described for use with mammalian (e.g., Neumann et al.. EMBO J. 1 :841-845. 1982) and fungal (e.g.. Meilhoc et al.. Bio/Technology 8:223- 227. 1990) host cells. However, the actual mechanism by which DNA is transferred into the cells is not well understood. For transformation of P. methanolica. it has been found that electroporation is surprisingly efficient when the cells are exposed to an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm and a time constant (τ) of from 1 to 40 milliseconds. The time constant τ is defined as the time required for the initial peak voltage V0 to drop to a value of V0/e. The time constant can be calculated as the product of the total resistance and capacitance of the pulse circuit, i.e., τ = R x C. Typically, resistance and capacitance are either preset or may be selected by the user, depending on the electroporation equipment selected. In any event, the equipment is configured in accordance with the manufacturer's instructions to provide field strength and decay parameters as disclosed above. Electroporation equipment is available from commercial suppliers (e.g., BioRad Laboratories. Hercules. CA).
DNA molecules for use in transforming P. methanolica will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation. For polypeptide or protein production, the DNA molecules will include, in addition to the selectable marker disclosed above, an expression casette comprising a transcription promoter, a DNA segment (e.g., a cDN A) encoding the polypeptide or protein of interest, and a transcription terminator. These elements are operably linked to provide for transcription of the DNA segment of interest. It is preferred that the promoter and terminator be that of a P. methanolica gene. Useful promoters include those from constitutive and methanol-inducible promoters. Promoter sequences are generally contained within 1.5 kb upstream of the coding sequence of a gene, often within 1 kb or less. In general, regulated promoters are larger than constitutive promoters due the presence of regulatory elements. Methanol-inducible promoters, which include both positive and negative regulatory elements, may extend more than 1 kb upstream from the initiation ATG. Promoters are identified by function and can be cloned according to known methods.
A particularly preferred methanol-inducible promoter is that of a P. methanolica alcohol utilization gene. A representative coding strand sequence of one such gene. AUG1. is shown in SEQ ID NO:2. Within SEQ ID NO:2. the initiation ATG codon is at nucleotides 1355- 1357. Nucleotides 1-23 of SEQ ID NO:2 are non-AUGl polylinker sequence. It is particularly preferred to utilize as a promoter a segment comprising nucleotides 24-1354 of SEQ ID NO:2, although additional upstream sequence can be included. P. methanolica contains a second alcohol utilization gene. A UG2. the promoter of which can be used within the present invention. A partial
DNA sequence of one AUG2 clone is shown in SEQ ID NO:9. AUG2 promoter segments used within the present invention will generally comprise nucleotides 91-169 of SEQ ID NO:9. although small truncations at the 3' end would not be expected to negate promoter function. Other useful promoters include those of the dihydroxyacetone synthase (DHAS). formate dehydrogenase (FMD). and catalase (CAT) genes. Genes encoding these enzymes from other species have been described. and their sequences are available (e.g.. Janowicz et al.. Nuc. Acids Res. 11:2043. 1985: Hollenberg and Janowicz. EPO publication 0 299 108, Didion and Roggenkamp FEBS Lett 301 1 13. 1992) Genes encoding these proteins can be cloned by using the known sequences as probes, or
Figure imgf000009_0001
aligning known sequences, designing primers based on the alignment, and amplifying P methanolica DNA by the polymerase chain reaction (PCR) Constitutive promoters are those that are not activated or inactivated b\ environmental conditions, they are always transcπptionallv active Preferred constitutive promoters for use within the present invention include those from glyceraldehyde-3-phosphate dehvdrogenase. tπose phosphate isomerase. and phosphoglycerate kinase genes of P methanolica These genes can be cloned by complementation in a host cell, such as a Saccharomyces cerevisiae cell, having a mutation in the counterpart gene Mutants of this type are well known in the an See. for example, Kawasaki and Fraenkel. Biochem Biophys Res Comm 108 1 107-1 1 12. 1982. McKnight et al . Cell 46 143-147. 1986. Aguilera and Zimmermann. Mol Gen Genet 202 83-89, 1986
The DNA molecules will further include a selectable marker to allow for identification, selection, and maintenance of transformants The DNA molecules may further contain additional elements, such an origin of replication and a selectable marker that allow amplification and maintenance of the DNA in an alternate host (e g , £ coli) To facilitate integration of the DNA into the host chromosome, it is preferred to have the entire expression segment, comprising the promoter-gene of interest-terminator plus selectable marker, flanked at both ends
Figure imgf000009_0002
including 3 untranslated DNA sequence at the downstream end of the expression segment and relying on the promoter sequence at the 5' end When using linear DNA, the expression segment will be flanked by cleavage sites to allow for linearization of the molecule and separation of the expression segment from other sequences (e g , a bacterial origin of replication and selectable marker) Preferred such cleavage sites are those that are recognized by restriction endonucleases that cut infrequently within a DNA seαuence. such as those that recognize 8-base target sequences (e . Not I)
Proteins that can be produced in P methanolica include proteins ot industrial and pharmaceutical interest Such proteins include higher eukaryotic proteins from plants and animals, particularly vertebrate animals such as mammals, although certain proteins from microorganisms are also of great value Proteins that can be prepared using methods of the present invention include enzvmes such as Upases, cellulases, and proteases, enzyme inhibitors, including protease inhibitors, growth factors such as platelet derived growth factor, fibroblast growth factors, and epidermal growth factor, cytokines such as erythropoietin and thrombopoietm. and hormones such as insulin, leptin. and glucagon
For production of polypeptides. P methanolica cells are cultured in a medium compπsing adequate sources of carbon, nitrogen and trace nutrients at a temperature of about 25°C to 35°C Liquid cultures are provided with sufficient aeration by conventional means, such as shaking ol small flasks or sparging of fermentors A preferred culture medium is YEPD (Table 1) The cells av be passaged by dilution into fresh culture medium or stored for snort periods on plates under refrigeration For long-term storage, the cells are preferablv kept in a 50% glvcerol solution at -70°C
Table 1 YEPD
2% D-glucose
2% Bacto™ Peptone (Difco Laboratories. Detroit. MI) 1 % Bacto™ yeast extract (Difco Laboratories) 0.004% adenine
0.006%) L-leucine
Table 1. continued
APE D
0.056% -Ade -Tip -Thr powder 0.67% yeast nitrogen base without amino acids 2% D-glucose
0.5% 200X tryptophan. threonine solution ADE PS
0.056%o -Ade -Trp -Thr powder 0.67% yeast nitrogen base without amino acids 2% D-glucose
0.5% 200X tryptophan. threonine solution 18.22% D-sorbitol LEU D
0.052%) -Leu -Trp -Thr powder 0.67% yeast nitrogen base without amino acids
2% D-glucose
0.5% 200X tryptophan. threonine solution HIS D
0.052%) -His -Trp -Thr powder 0.67% yeast nitrogen base without amino acids
2% D-glucose
0.5%) 200X tryptophan. threonine solution URA D
0.056% -Ura -Trp -Thr powder 0.67% yeast nitrogen base without amino acids
2% D-glucose
0.5% 200X tryptophan. threonine solution URA PS
0.056%) -Ura -Trp -Thr powder 0.67% yeast nitrogen base without amino acids
2% P-glucose
0.5% 200X tryptophan, threonine solution
18.22% P-sorbitol Table 1 , continued -Leu -Trp -Thr powder powder made
Figure imgf000012_0001
combining 4 0 g adenine. 3 0 g arginine. 5 0 g aspartic acid. 2 0 g histidine 6 0 g isoleucine. 4 0 g lysine. 2 0 g methionme. 6 0 g phenylalanine. 5 0 g seπne 5 0 g tyrosme. 4 0 g uracil. and 6 0 g valine (all L- amino acids)
-His -Trp -Thr powder powder made by combining 4 0 g adenine. 3 0 g arginme. 5 0 g aspartic acid. 6 0 g isoleucine. 8 0 g Ieucme, 4 0 g lysine. 2 0 g methionme. 6 0 g phenylalanine. 5 0 g seπne.
5 0 g tyrosme. 4 0 g uracil, and 6 0 g valine (all L- amino acids) -Ura -Trp -Thr powder powder made by combining 4 0 g adenine, 3 0 g arginine. 5 0 g aspartic acid. 2 0 g histidine.
6 0 g isoleucine. 8 0 g leucine. 4 0 g lysine, 2.0 g methionme, 6 0 g phenylalanine. 5 0 g seπne. 5 0 g tyrosme. and 60 g valine (all L- amino acids)
-Ade -Trp -Thr powder powder made
Figure imgf000012_0002
combining 3 0 g arginine. 5 0 g aspartic acid, 2 0 g histidine. 6 0 g isoleucine. 8 0 g leucine. 4 0 g lysine. 2 0 g methionme. 6 0 g phenylalanine. 5 0 g seπne 5 0 g tyrosme. 4 0 g uracil. and 6 0 g valine (all L- amino acids) 200X tryptophan. threonine solution
3 0%) L-threomne. 0 8% L-tryptophan in H20 For plates, add 1 8% Bacto™ agar (Pifco Laboratories)
Electroporation of P methanolica is preferably carried out on cells in early log phase growth Cells are streaked to single colonies on solid media, preferably solid YEPD After about 2 days of growth at 30°C. single colonies from a fresh plate are used to inoculate the desired volume of rich culture media (e g , YEPD) to a cell density of about 5 - 10 x 103 cells/ml Cells are incubated at about 25 - 35°C. preferably 30°C. with vigorous shaking, until thev are in earh log phase The cells are then harvested, such as by centπfugation at 3000 x g for 2-3 minutes, and resuspended Cells are made electrocompetent by reducing disulfide bonds in the cell walls. equilibrating them m an ionic solution that is compatible with the electroporation conditions, and chilling them Cells are typically made electrocompetent by incubating them in a buffered solution at pH 6-8 containing a reducing agent, such as dithiothreitol (DTT) or β-mercaptoethanol (BME). to reduce cell wall proteins to facilitate subsequent uptake of DNA A preferred incubation buffer in this regard is a fresh solution of 50 mM potassium phosphate buffer. pH 7 5. containing 25 mM DTT. The cells are incubated in this buffer (typically using one-fifth the original culture volume) at about 30°C for about 5 to 30 minutes, preferably about 15 minutes The cells are then harvested and washed in a suitable electroporation buffer, which is used ice-cold Suitable buffers in this regard include pH 6-8 solutions containing a weak buffer, divalent cations (e . Mg Ca""1") and an osmotic stabilizer (e.g . a sugar) After washing, the cells are resuspended in a small \olume ot the buffer, at which time they are electrocompetent and can be used directly or ahquoπed and stored frozen (preferably at -70°C) A preferred electroporation buffer is STM (270 mM sucrose, 10 mM
Tπs, pH 7 5. 1 mM MgCh) Within a preferred protocol, the cells are subjected to two washes first in the oπgmal culture volume of ice-cold buffer, then in one-half the oπginal volume Following the second wash, the cells are harvested and resuspended typically using about 3-5 ml of buffer for an original culture volume of 200 ml
Electroporation is earned out using a small volume of electrocompetent cells (typically about 100 μl) and up to one-tenth volume of linear DNA molecules For example, 0 1 ml of cell suspension in a buffer not exceeding 50 mM in ionic strength is combined with 0 1-10 μg of DNA (vol < 10 μl) This mixture is placed in an ice-cold electroporation cuvette and subjected to a pulsed electric field of from 2 5 to 4 5 kV/cm, preferably about 3 75 kV/cm. and a time constant of from 1 to 40 milliseconds, preferably 10-30 milliseconds, more preferably 15-25 milliseconds, most preferably about 20 milliseconds, with exponential decay The actual equipment settings used to achieve the desired pulse parameters will be determined by the equipment used When using a BioRad (Hercules. CA) Gene Pulser™ electroporator with a 2 mm electroporation cuvette, resistance is set at 600 ohms or greater, preferably "infinite' resistance, and capacitance is set at 25 μF to obtain the desired field characteristics After being pulsed, the cells are diluted approximately 1 OX into 1 ml of YEPD broth and incubated at 30°C for one hour
The cells are then harvested and plated on selective media Within a preferred embodiment, the cells are washed once with a small volume (equal to the diluted volume of the electroporated cells) of IX yeast nitrogen base (6 7 g/L yeast nitrogen base without ammo acids, Difco Laboratories. Detroit, MI), and plated on minimal selective media Cells having an ade2 mutation that have been transformed with an ADE2 selectable marker can be plated on a minimal medium that lacks adenine. such as ADE D (Table 1 ) or ADE DS (Table 1 ) In a typical procedure, 250 μl aliqouts of cells are plated on 4 separate ADE D or ADE DS plates to select for Ade+ cells
P methanolica recognizes certain infrequently occuπng sequences, termed autonomously replicating sequences (ARS). as ongms of DNA replication, and these sequences may fortuitously occur within a DNA molecule used for transformation, allowing the transforming DNA to be maintained extrachromosomalh However, integrative transformants are generally preferred for use in protein production systems Integrative transformants have a profound growth advantage over ARS transformants on selective media containing sorbitol as a carbon source, thereby providing a method for selecting integrative transformants from among a population of transformed cells ARS sequences have been found to exist in the ADE2 gene and. possibly, the
A UG1 gene of P methanolica ade2 host cells of Pichia methanolica transformed with an ADE2 gene can thus become Ade+ by at least two different modes The ARS within the ADE2 gene allows unstable extrachromosomal maintenance of the transforming DNA (Hiep et al . Yeast 9 1 189-1 197 1993) Colonies of such transformants are characterized by slower growth rates and pink color due to prolific generation of progeny that are Ade" Transforming DNA can also integrate into the host genome, giving rise to stable transformants that grow rapidly are white, and that fail to give rise to detectable numbers of Ade" progen\ ADE D plates allow the most rapid growth of transformed cells, and unstable and stable transformants grow at roughh the same rates After 3-5 days of incubation on ADE D plates at 30°C stable transformant colonies are white and roughlv twice the size of unstable, pink transformants ADE DS plates are more selective for stable transformants. which form large (s.5 mm) colonies in 5-7 days, while unstable (ARS -maintained) colonies are much smaller (»1 mm) The more selective ADE DS media is therefore preferred for the identification and selection of stable transformants For some applications such as the screening ot genetically diverse libraries for rare combinations of genetic elements it is sometimes desirable to screen large numbers of unstable transformants. which have been observed to outnumber stable transformants by a factor of roughly 100 In such cases, those skilled in the art will recognize the utility of plating transformant cells on less selective media, such as ADE D
Integrative transformants are preferred for use in protein production processes Such cells can be propagated without continuous selective pressure because DNA is rareh lost from the genome Integration of DNA into the host chromosome can be confirmed
Figure imgf000014_0001
Southern blot analysis Briefly, transformed and untransformed host DNA is digested with restπction endonuc leases, separated by electrophoresis, blotted to a support membrane, and probed with appropπate host DNA segments Differences in the patterns of fragments seen in untransformed and transformed cells are indicative of integrative transformation Restriction enzλmes and probes can be selected to identify transforming DNA segments (e g . promoter terminator heterologous DNA. and selectable marker sequences) from among the genomic fragments
Differences in expression levels of heterologous proteins can result from such factors as the site of integration and copy number of the expression cassette and differences m promoter activity among individual isolates It is therefore advantageous to screen a number of isolates for expression level prior to selecting a production strain A variety of suitable screening methods are available For example, transformant colonies are grown on plates that are overlayed with membranes (e g , nitrocellulose) that bind protein Proteins are released from the cells by secretion or following lysis, and bind to the membrane Bound protein can then be assaved using known methods, including immunoassays More accurate analysis of expression levels can be obtained b\ culturing cells in liquid media and analvzing conditioned media or cell lysates as appropπate Methods for concentrating and puπfying proteins from media and lysates will be determined in pan by the protein of interest Such methods are readily selected and practiced
Figure imgf000014_0002
the skilled practitioner
For small-scale protein production (e g , plate or shake flask production), P methanolica transformants that carry an expression cassette compπsing a methanol-regulated promoter (such as the AUGl promoter) are grown in the presence of methanol and the absence of mterfenng amounts of other carbon sources (e g , glucose) For small-scale experiments, including preliminary screening of expression levels, transformants may be grown at 30°C on solid media containing, for example. 20 g/L Bacto-agar (Difco). 6 7 g/L yeast nitrogen base without am o acids (Difco). 10 g/L methanol, 0 4 μg/L biotin. and 0 56 g/L of -Ade -Thr -Trp powder Because methanol is a volatile carbon source it is readily lost on prolonged incubation A continuous supph of methanol can be provided by placing a solution of 50% methanol in water in the lids of inverted plates, whereby the methanol is transferred to the growing cells bv evaporative transier In general not more than 1 mL of methanol is used per 100-mm plate Slightlv larger scale expeπments can be earned out using cultures grown in shake flasks In a typical procedure, cells are cultivated for two days on minimal methanol plates as disclosed above at 30°C. then colonies are used to inoculate a small volume of minimal methanol media (6 7 g/L veast nitrogen base without amino acids. 10 g/L methanol. 0.4 μg/L biotin) at a cell density of about 1 x 10^ cells/ml. Cells are grown at 30°C. Cells growing on methanol have a high oxygen requirement, necessitating vigorous shaking during cultivation. Methanol is replenished daily (typically 1/100 volume of 50% methanol per day).
For production scale culturing, fresh cultures of high producer ciones are prepared in shake flasks. The resulting cultures are then used to inoculate culture medium in a fermenter.
Typically, a 500 ml culture in YEPD grown at 30°C for 1-2 days with vigorous agititation is used to inoculate a 5-liter fermenter. The cells are grown in a suitable medium containing salts, glucose, biotin, and trace elements at 28°C, pH 5.0. and >30% dissolved Oi- After the initial charge of glucose is consumed (as indicated by a decrease in oxygen consumption), a glucose/methanol feed is delivered into the vessel to induce production of the protein of interest. Because large-scale fermentation is carried out under conditions of limiting carbon, the presence of glucose in the feed does not repress the methanol-inducible promoter. The use of glucose in combination with methanol under glucose-limited conditions produces rapid growth, efficient conversion of carbon to biomass and rapid changes in physiological growth states, while still providing full induction of methanol-inducible gene promoters. In a typical fermentation run. a cell density of from about 80 to about 400 grams of wet cell paste per liter is obtained. "Wet cell paste" refers to the mass of cells obtained by harvesting the cells from the fermentor. typically by centrifugation of the culture.
The invention is further illustrated by the following non-limiting examples.
Examples
Example 1
P. methanolica cells (strain CBS6515 from American Type Culture Collection.
Rockville. MD) were mutagenized by UV exposure. A killing curve was first generated by plating cells onto several plates at approximately 200-250 cells/plate. The plates were then exposed to UV radiation using a G8T5 germicidal lamp (Sylvania) suspended 25 cm from the surfaces of the plates for periods of time as shown in Table 2. The plates were then protected from visible light sources and incubated at 30°C for two days.
Table 2
Viable Cells
Time Plate 1 Plate 2 Average
0 sec 225 229 227
1 sec 200 247 223
2 sec 176 185 181
4 sec. 149 86 1 18
8 sec 20 7 14
16 sec 0 2 1
Large-scale mutagenesis was then carried out using a 2-second UV exposure to provide about 20%o killing. Cells were plated at approximately 104 cells/plate onto eight YEPD plates that were supplemented with 100 mg/L each of uracil. adenine. and leucine. which were added to supplement the growth of potential auxotrophs having the cognate deficiencies Following UV exposure the plates were wrapped in foil and incubated overnight at 30°C The following day the colonies on the plates (-10* total) were resuspended in water and washed once with water An amount of cell suspension sufficient to give an ODgQO of 0 1 - 0 2 was used to inoculate 500 ml of minimal broth made with yeast nitrogen base without amino acids or ammonia, supplemented with 1% glucose and 400 μg/L biotin. The culture was placed in a 2 8 L baffled Bell flask and shaken vigorously overnight at 30°C. The following day the cells had reached an ODgQO of -1 0 - 2.0 The cells were pelleted and resuspended in 500 ml of minimal broth supplemented with 5 g/L ammonium sulfate. The cell suspension was placed in a 2.8 L baffled Bell flask and shaken vigorously at 30°C for 6 hours 50 ml of the culture was set aside in a 250-ml flask as a control, and to the remainder of the culture was added 1 mg nystatin (Sigma Chemical Co . St Louis. MO) to select for auxotrophic mutants (Snow. Nature 211.206-207. 1966) The cultures were incubated with shaking for an additional hour The control and nystatin-treated cells were then harvested
Figure imgf000016_0001
centπfugation and washed with water three times The washed cells were resuspended to an OD 00 of 1.0 in 50%> glycerol and frozen Titeπng of nystatin-treated cells versus the control cells for colony forming units revealed that nystatin ennchment had decreased the number of viable cells by a factor of 104
10"2 dilutions of nystatin-treated cells were plated on 15 YEPD plates Colonies were replica-plated onto minimal plates (2% agar. 1 x YNB. 2% glucose. 400 μg/L biotin) The frequency of auxotrophs was about 2 - 4%> Approximately 180 auxotrophic colonies were picked to YEPD + Ade. Leu. Ura plates and replica-plated to various dropout plates All of the auxotrophs were Ade" Of these. 30 were noticably pink on dropout plates (LEU D. HIS D. etc . see Table 1)
Of the 30 pink mutants. 21 were chosen for further study , the remainder were either leak\ for growth on ADE D plates or contaminated with wiid-type cells
The Ade" mutants were then subjected to complementation analysis and phenotvpic testing To determine the number of loci defined by the mutants, all 21 mutants were mated to a single pink. Ade" tester strain (strain #2) Mating was earned out by mixing cell suspensions
(ODgQO = 1 ) and plating the mixtures in 10 ul aliquots on YEPD plates The cells were then replicated to SPOR media (0.5%> Na acetate. 1% KCl. 1% glucose. 1% agar) and incubated overnight at 30°C. The cells were then replica-plated to ADE D plates for scoring of phenotype. As shown in Table 3. some combinations of mutants failed to give Ade+ colonies (possibly defining the same genetic locus as in strain #2), while others gave rise to numerous Ade+ colonies (possibly defining a separate genetic locus). Because mutant #3 gave Ade+ colonies when mated to #2. complementation testing was repeated with mutant #3. If the group of mutants defined two genetic loci, then all mutants that failed to give Ade+ colonies when mated to strain #2 should give Ade+ colonies when mated to #3. Results of the crosses are shown in Table 3.
Table 3
Mutant x Mutant #2 x Mutant #3
#1 + -
#3 + -
#10 + -
#15 -t- -
#18 + -
#24 + -
#28 + -
#30 -r -
#2 - +
#6 - +
#8 - +
#9 - +
#1 1 - +
#17 - +
#19 - +
#20 - +
Table 3. continued
#22 . +
#27 - +
#4 +
#12 ~ +
#16 ~ +
As shown in Table 3. most mutants fell into one of two groups, consistent with the idea that there are two adenine biosynthetic genes that, when missing, result in pink colonies on limiting adenine media. Three colonies (#4. #12. and #16) may either define a third locus or exhibit intragemc complementation. Two intensely pigmented mutants from each of the two complementation groups (#3 and #10: #6 and #1 1) were selected for further characterization. Additional analysis indicated that Ade" was the only auxotrophy present in these strains. A P. methanolica clone bank was constructed in the vector pRS426. a shuttle vector comprising 2μ and S. cerevisiae URA3 sequences, allowing it to be propagated in S. cerevisiae. Genomic DNA was prepared from strain CBS6515 according to standard procedures. Briefly, cells were cultured overnight in rich media, spheroplasted with zymolyase. and lysed with SDS. DNA was precipitated from the lysate with ethanol and extracted with a phenol/chloroform mixture, then precipitated with ammonium acetate and ethanol. Gel eiectrophoresis of the DNA preparation showed the presence of intact, high molecular weight DNA and appreciable quantities of RNA. The DNA was partially digested with Sau 3 A by incubating the DNA in the presence of a dilution series of the enzyme. Samples of the digests were analyzed by eiectrophoresis to determine the size distribution of fragments. DNA migrating between 4 and 12 kb was cut from the gel and extracted from the gel slice. The size-fractionated PNA was then ligated to pRS426 that had been digested with Bam HI and treated with alkaline phosphatase. Aliquots of the reaction mixture were electroporated in E. coli MCI 061 cells using a BioRad Gene Pulser™ device as recommended by the manufacturer. The genomic library was used to transform S. cerevisiae strain HBY21 A (ade2 ura3) by electroporation (Becker and Guarente. Methods Enzvmol. 194: 182-187. 1991 ). The cells were resuspended in 1.2 M sorbitol, and six 300-μl aliquots were plated onto ADE D, ADE DS, URA D and URA DS plates (Table 1 ). Plates were incubated at 30°C for 4-5 days. No Ade"1" colonies were recovered on the ADE D or ADE DS plates. Colonies from the URA D and URA DS plates were replica-plated to ADE D plates, and two closely spaced, white colonies were obtained. These colonies were restreaked and confirmed to be Ura"1" and Ade"^. These two strains, designated Adel and Ade6. were streaked onto media containing 5 FOA (5 fluoro orotic acid; Sikorski and Boeke, Methods Enzvmol. 194:302-318). Ura" colonies were obtained, which were found to be Ade" upon replica plating. These results indicate that the Ade+ complementing activity is genetically linked to the plasmid-borne URA3 marker. Plasmids obtained from yeast strains Adel and Adeό appeared to be identical by restriction mapping as described below. These genomic clones were designated pADEl-1 and pADEl-6, respectively.
Total DNA was isolated from the HBY21A transformants Adel and Adeό and used to transform E. coli strain MCI 061 to AmpR. DNA was prepared from 2 AmpR colonies of Adel and 3 AmpR colonies of Adeό. The DNA was digested with Pst I. Sea I, and Pst I + Sea I and analyzed by gel eiectrophoresis. All five isolates produced the same restriction pattern.
PCR primers were designed from the published sequence of the P. methanolica ADE2 gene (also known as ADE1 Hiep et al.. Yeast 9:1251-1258. 1993). Primer 9080 (SEQ ID NO:3) was designed to prime at bases 406-429 of the ADE2 DNA (SEQ ID NO:l), and primer 9079 (SEQ ID NO:4) was designed to prime at bases 2852-2829. Both primers included tails to introduce Avr II and Spe I sites at each end of the amplified sequence. The predicted size of the resulting PCR fragment was 2450 bp.
PCR was carried out using plasmid DNA from the five putative ADE2 clones as template DNA. The 100 μl reaction mixtures contained l Taq PCR buffer (Boehringer Mannheim. Indianapolis. IN), 10-100 ng of plasmid DNA. 0.25 mM dNTPs. 100 pmol of each primer, and 1 μl
Taq polymerase (Boehringer Mannheim). PCR was run for 30 cycles of 30 seconds at 94°C. 60 seconds at 50°C, and 120 seconds at 72°C. Each of the five putative ADE2 genomic clones yielded a PCR product of the expected size (2.4 kb). Restriction mapping of the DNA fragment from one reaction gave the expected size fragments when digested with Bgl II or Sal I.
The positive PCR reactions were pooled and digested with Spe I. Vector pRS426 was digested with Spe I and treated with calf intestinal phosphatase. Four μl of PCR fragment and 1 μl of vector DNA were combined in a 10 μl reaction mix using conventional ligation conditions. The ligated DNA was analyzed by gel eiectrophoresis. Spe I digests were analyzed to identify plasmids carrying a subclone of the ADE2 gene within pRS426. The correct plasmid was designated pCZRl 18. Because the ADE2 gene in pCZR118 had been amplified by PCR, it was possible that mutations that disabled the functional character of the gene could have been generated. To test for such mutations, subclones with the desired insert were transformed singly into Saccharomyces cerevisiae strain HBY21A. Cells were made electrocompetent and transformed according to standard procedures. Transformants were plated on URA D and ADE D plates. Three phenotypic groups were identified. Clones 1, 2, 1 1, and 12 gave robust growth of many transformants on ADE D. The transformation frequency was comparable to the frequency of Ura+ transformants. Clones 6, 8, 10, and 14 also gave a high efficiency of transformation to both Ura+ and Ade'. but the Ade+ colonies were somewhat smaller than those in the first group. Clone 3 gave many Ura+ colonies, but no Ade4" colonies, suggesting it carried a non-functional ade2 mutation. Clones 1. 2, 11, and 12 were pooled.
To identify the P. methanolica ade2 complementation group, two representative mutants from each complementation group (#3 and #10; #6 and #11), which were selected on the basis of deep red pigmentation when grown on limiting adenine. were transformed with the cloned ADE gene. Two hundred ml cultures of early log phase cells were harvested by centrifugation at 3000 x g for 3 minutes and resuspended in 20 ml of fresh KD buffer (50 mM potassium phosphate buffer, pH 7.5, containing 25 mM DTT). The cells were incubated in this buffer at 30°C for 15 minutes. The cells were then harvested and resuspended in 200 ml of ice-cold STM (270 mM sucrose, 10 mM Tris, pH 7.5, 1 mM MgCl2). The cells were harvested and resuspended in 100 ml of ice-cold STM. The cells were again harvested and resuspended in 3-5 ml of ice-cold STM. 100- μl aliquouts of electrocompetent cells from each culture were then mixed with Not I-digested pADEl-1 DNA. The cell/DNA mixture was placed in a 2 mm electroporation cuvette and subjected to a pulsed electric field of 5 kV/cm using a BioRad Gene Pulser™ set to 1000Ω resistance and capacitance of 25 μF. After being pulsed, the cells were diluted by addition of 1 ml YEPD and incubated at 30°C for one hour. The cells were then harvested by gentle centrifugation and resuspended in 400 μl minimal selective media lacking adenine (ADE D). The resuspended samples were split into 200-μl aliqouts and plated onto ADE D and ADE DS plates. Plates were incubated at 30°C for 4-5 days. Mutants #6 and #11 gave Ade+ transformants. No Ade+ transformants were observed when DNA was omitted, hence the two isolates appeared to define the ade2 complementation group. The ADE2 sequence is shown in SEQ ID NO: 1.
Example 2 The P. methanolica clone bank disclosed in Example 1 was used as a source for cloning the Alcohol Utilization Gene (AUGl). The clone bank was stored as independent pools. each representing about 200-250 individual genomic clones. 0.1 μl of "miniprep" DNA from each pool was used as a template in a polymerase chain reaction with PCR primers (8784. SEQ ID NO:5; 8787, SEQ ID NO:6) that were designed from an alignment of conserved sequences in alcohol oxidase genes from Hansenula polymorpha. Candida boidini, and Pichia pastoris. The amplification reaction was run for 30 cycles of 94°C, 30 seconds; 50°C, 30 seconds; 72°C, 60 seconds; followed by a 7 minute incubation at 72°C. One pool (#5) gave a -600 bp band. DNA sequencing of this PCR product revealed that it encoded an amino acid sequence with -70% sequence identity with the Pichia pastoris alcohol oxidase encoded by the AOXl gene and about
85%o sequence identity with the Hansenula polymorpha alcohol oxidase encoded by the MOX1 gene. The sequence of the cloned AUGl gene is shown in SEQ ID NO:2.
Sub-pools of pool #5 were analyzed by PCR using the same primers used in the initial amplification. One positive sub-pool was further broken down to identify a positive colony. This positive colony was streaked on plates, and DNA was prepared from individual colonies. Three colonies gave identical patterns after digestion with Cla I.
Restriction mapping of the genomic clone and PCR product revealed that the AUGl gene lay on a 7.5 kb genomic insert and that sites within the PCR fragment could be uniquely identified within the genomic insert. Because the orientation of the gene within the PCR fragment was known, the latter information provided the approximate location and direction of transcription of the AUGl gene within the genomic insert. DNA sequencing within this region revealed a gene with very high sequence similarity at the amino acid level to other known alcohol oxidase genes.
Example 3 ade2 mutant P. methanolica cells are transformed by electroporation essentially as disclosed above with an expression vector comprising the A UG1 promoter and terminator, human GAD65 DNA (Karlsen et al., Proc. Natl. Acad. Sci. USA 88:8337-8341, 1991), and ADE2 selectable marker. Colonies are patched to agar minimal methanol plates ( 10 to 100 colonies per 100-mm plate) containing 20 g/L Bacto™-agar (Difco), 6.7 g/L yeast nitrogen base without amino acids (Difco), 10 g/L methanol, and 0.4 μg/L biotin. The agar is overlayed with nitrocellulose, and the plates are inverted over lids containing 1 ml of 50% methanol in water and incubated for 3 to 5 days at 30°C. The membrane is then transferred to a filter soaked in 0.2 M NaOH. 0.1% SDS, 35 mM dithiothreitol to lyse the adhered cells. After 30 minutes, cell debris is rinsed from the filter with distilled water, and the filter is neutralized by rinsing it for 30 minutes in 0.1 M acetic acid. The filters are then assayed for adhered protein. Unoccupied binding sites are blocked by rinsing in TTBS-NFM (20 mM Tris pH 7.4. 0.1% Tween 20, 160 mM NaCl. 5% powdered nonfat milk) for 30 minutes at room temperature. The filters are then transferred to a solution containing GAD6 monoclonal antibody (Chang and Gottlieb. J. Neurosci. 8:2123-2130. 1988), diluted 1:1000 in TTBS-NFM. The filters are incubated in the antibody solution with gentle agitation for at least one hour, then washed with TTBS (20 mM Tris pH 7.4, 0.1%) Tween 20, 160 mM NaCl) two times for five minutes each. The filters are then incubated in goat anti-mouse antibody conjugated to horseradish peroxidase (1 μg/ml in TTBS-NFM) for at least one hour, then washed three times, 5 minutes per wash with TTBS. The filters are then exposed to commercially available chemilu inescence reagents (ECL™; Amersham Inc., Arlington Heights. IL). Light generated from positive patches is detected on X-ray film. To more accurately detect the level of GADg5 expression, candidate clones are cultured in shake flask cultures. Colonies are grown for two days on minimal methanol plates at 30 °C as disclosed above. The colonies are used to inoculate 20 ml of minimal methanol media (6.7 g/L yeast nitrogen base without amino acids, 10 g/L methanol. 0.4 μg L biotin) at a cell density of 1 x lθ6 cells/ml. The cultures are grown for 1-2 days at 30°C with vigorous shaking. 0.2 ml of 50%) methanol is added to each culture daily. Cells are harvested by centrifugation and suspended in ice- cold lysis buffer (20 mM Tris pH 8.0, 40 mM NaCl. 2 mM PMSF, 1 mM EDTA, 1 μg/ml leupeptin. 1 μg ml pepstatin, 1 μg/ml aprotinin) at 10 ml final volume per 1 g cell paste. 2.5 ml of the resulting suspension is added to 2.5 ml of 400-600 micron, ice-cold, acid-washed glass beads in a 15-ml vessel, and the mixture is vigorously agitated for one minute, then incubated on ice for 1 minute. The procedure is repeated until the cells have been agitated for a total of five minutes. Large debris and unbroken cells are removed by centrifugation at 1000 x g for 5 minutes. The clarified lysate is then decanted to a clean container. The cleared lysate is diluted in sample buffer (5% SDS, 8 M urea. 100 mM Tris pH 6.8, 10% glycerol, 2 mM EDTA, 0.01% bromphenol glue) and electrophoresed on a 4-20% acrylamide gradient gel (Novex, San Diego, CA). Proteins are blotted to nitrocellose and detected with GAD6 antibody as disclosed above.
Clones exhibiting the highest levels of methanol-induced expression of foreign protein in shake flask culture are more extensively analyzed under high cell density fermentation conditions. Cells are first cultivated in 0.5 liter of YEPD broth at 30°C for 1 - 2 days with vigorous agitation, then used to inoculate a 5-liter fermentation apparatus (e.g., BioFlow III; New Brunswick Scientific Co., Inc.. Edison, NJ). The fermentation vessel is first charged with mineral salts by the addition of 57.8 g (NH4)2S0 , 68 g ICH2P04, 30.8 g MgS04-7H20. 8.6 g CaS04-2H20, 2.0 g NaCl, and 10 ml antifoam (PPG). H2O is added to bring the volume to 2.5 L, and the solution is autoclaved 40 minutes. After cooling, 350 ml of 50%> glucose, 250 ml 10 X trace elements (Table
4), 25 ml of 200 μg/ml biotin, and 250 ml cell inoculum are added.
Table 4
10 X trace elements:
FeSO4-7H20 lOOmM 27.8 g/L
CuS04-5H 0 2mM 0.5 g/L
ZnCl 8mM 1.09 g/L
MnS0 H20 8mM 1.35 g/L
CoCl2-6H 0 2mM 0.48 g/L
Na2Mo0 -2H 0 ImM 0.24 g/L
H3BO3 8mM 0.5 g/L
KI 0.5mm 0.08 g/L biotin 5mg/L thiamine 0.5 g/L
Add 1-2 mis H2S0 per liter to bring compounds into solution.
The fermentation vessel is set to run at 28°C, pH 5.0, and >30%> dissolved 02. The cells will consume the initial charge of glucose, as indicated by a shaip demand for oxygen during glucose consumption followed by a decrease in oxygen consumption after glucose is exhausted. After exhaustion of the initial glucose charge, a glucose-methanol feed supplemented with NHt * and trace elements is delivered into the vessel at 0.2% (w/v) glucose, 0.2% (w/v) methanol for 5 hours followed by 0.1 %> (w/v) glucose. 0.4% (w/v) methanol for 25 hours. A total of 550 grams of methanol is supplied through one port of the vessel as pure methanol using an initial delivery rate of 12.5 ml/hr and a final rate of 25 ml/hr. Glucose is supplied through a second port using a 700 ml solution containing 175 grams glucose, 250 ml 10X trace elements, and 99 g (NH-ι)2S04. Under these conditions the glucose and methanol are simultaneously utilized, with the induction of GAD65 expression upon commencement of the glucose-methanol feed. Cells from the fermentation vessel are analyzed for GAD55 expression as described above for shake flask cultures.
Cells are removed from the fermentation vessel at certain time intervals and subsequently analyzed. Little GADg5 expression is observed during growth on glucose.
Exhaustion of glucose leads to low level expression of the GAD65 protein; expression is enhanced by the addition of MeOH during feeding of the fermentation culture. The addition of methanol has a clear stimulatory effect of the expresion of human GADβ5 driven by the methanol-responsive AUGl promoter.
Example 4
Transformation conditions were investigated to determine the electric field conditions. DNA topology, and DNA concentration that were optimal for efficient transformation of P. methanolica. All experiments used P. methanolica ade2 strain #1 1. Competent cells were prepared as previously described. Electroporation was carried out using a BioRad Gene Pulser™.
Three field parameters influence transformation efficiency by electroporation: capacitance, field strength, and pulse duration. Field strength is determined by the voltage of the electric pulse, while the pulse duration is determined by the resistance setting of the instrument. Within this set of experiments, a matrix of field strength settings at various resistances was examined. In all experiments, the highest capacitance setting (25 μF) of the instrument was used. 100 μl aliquots of electrocompetent cells were mixed on ice with 10 μl of DNA that contained approximately 1 μg of the ADE2 plasmid pCZR133 that had been linearized with the restriction enzyme Not I. Cells and DNA were transferred to 2 mm electroporation cuvettes (BTX Corp., San Diego, CA) and electropulsed at field strengths of 0.5 kV (2.5 kV/cm). 0.75 kV (3.75 kV/cm), 1.0 kV (5.0 kV/cm), 1.25 kV (6.25 kV/cm). and 1.5 kV (7.5 kV/cm). These field strength conditions were examined at various pulse durations. Pulse duration was manipulated by varying the instrument setting resistances to 200 ohms. 600 ohms, or "infinite" ohms. Pulsed cells were suspended in YEPD and incubated at 30°C for one hour, harvested, resuspended. and plated. Three separate sets of experiments were conducted. In each set, electroporation conditions of 0.75 kV (3.75 kV/cm) at a resistance of "infinite" ohms was found to give a dramatically higher transformation efficiency than other conditions tested (see Fig. 1 ).
After the optimal pulse conditions were established, the influence of DNA topology on transformation efficiency was investigated. Electrocompetent cells were mixed with I μg of uncut, circular pCZR133 or with 1 μg of Not I-digested pCZR133. In three separate experiments, an average of roughly 25 transformants were recovered with circular DNA while linear DNA yielded an average of nearly 1 x 104 transformants. These data indicate that linear DNA transforms P. methanolica with much greater efficiency than circular DNA.
Finally, the relationship between DNA concentration and transformation efficiency was investigated. Aliquots of linear pCZR133 DNA (1 ng, 10 ng, 100 ng and 1 μg in 10 μl H20) were mixed with 100 μl electrocompetent cells, and electroporation was carried out at 3.75 kV/cm and "infinite" ohms. The number of transformants varied from about 10 (1 ng DNA) to 104 (1 μg
DNA) and was found to be proportional to the DNA concentration.
Example 5
Integration of transforming DNA into the genome of P. methanolica was detected by comparison of DNA from wild-type cells and stable, white transformant colonies. Two classes of integrative transformants were identified. In the first, transforming DNA was found to have integrated into a homologous site. In the second class, transforming DNA was found to have replaced the endogenous AUG 1 open reading frame. While not wishing to be bound by theory, this second transformant is believed to have arisen by a "transplacement recombination event" (Rothstein, Methods Enzvmol. 194:281-301, 1991) whereby the transforming DNA replaces the endogenous DNA via a double recombination event.
P. methanolica ade2 strain #11 was transformed to Ade+ with Asp I-digested pCZR140, a Bluescript® (Stratagene Cloning Systems, La Jolla, CA)-based vector containing the P. methanolica ADE2 gene and a mutant of AUGl in which the entire open reading frame between the promoter and terminator regions has been deleted (Fig. 2). Genomic DNA was prepared from wild- type and transformant cells grown for two days on YEPD plates at 30°C. About 100-200 μl of cells was suspended in 1 ml H20, then centrifiiged in a microcentrifuge for 30 seconds. The cell pellet was recovered and resuspended in 400 μl of SCE + DTT + zymolyase (1.2 M sorbitol, 10 mM Na citrate, 10 mM EDTA, 10 mM DTT, 1-2 mg/ml zymolyase 100T) and incubated at 37°C for 10-15 minutes. 400 μl of 1%> SDS was added, and the solution was mixed until clear. 300 μl of 5 M potassium acetate, pH 8.9 was added, and the solution was mixed and centrifiiged at top speed in a microcentrifuge for five minutes. 750 μl of the supernatant was transferred to a new tube and extracted with an equal volume of phenol/chloroform. 600 μl of the resulting supernatant was recovered, and DNA was precipitated by the addition of 2 volumes of ethanol and centrifugation for 15 minutes in the cold. The DNA pellet was resuspended in 50 ml TE (10 mM Tris pH 8, 1 mM EDTA) + 100 μg/ml RNAase for about 1 hour at 65°C. 10-μl DNA samples were digested with Eco RI (5 μl) in a 100 μl reaction volume at 37°C overnight. DNA was precipitated with ethanol. recovered by centrifugation. and resuspended in 7.5 μl TE + 2.5 μl 5X loading dye. The entire 10 ml volume was applied to one lane of a 0.7%> agarose in 0.5 X TBE (10 X TBE is 108 g/L Tris base 7-9, 55 g/L boric acid. 8.3 g/L disodium EDTA) gel. The gel was run at 100 V in 0.5 X TBE containing ethidium bromide. The gel was photographed, and DNA was electrophoreticall transferred to a positively derivatized nylon membrane (Nytran® N+, Schleicher & Schuell, Keene, NH) at 400 mA, 20 mV for 30 minutes. The membrane was then rinsed in 2 X SSC. blotted onto denaturation solution for five minutes, neutralized in 2 X SSC. then cross-linked damp in a UV crosslinker (Stratalinker®, Stratagene Cloning Systems) on automatic setting. The blot was hybridized to a PCR-generated AUGl promoter probe using a commercially available kit (ECL™ kit, Amersham Corp., Arlington Heights. IL). Results indicated that the transforming DNA altered the structure of the AUGl promoter DNA, consistant with a homologous integration event (Fig. 2). In a second experiment, P. methanolica ade 2 strain #11 was transformed to Ade+ with Not I-digested pCZR137, a vector containing a human GAD65 cDNA between the AUGl promoter and terminator (Fig. 3). Genomic DNA was prepared as described above from wild-type cells and a stable, white, Ade+ transformant and digested with Eco RI. The digested DNA was separated by eiectrophoresis and blotted to a membrane. The blot was probed with a PCR- generated probe corresponding to either the AUGl open reading frame or the A UGl promoter. Results demonstrated that the A UGl open reading frame DNA was absent from the transformant strain, and that the AUGl promoter region had undergone a significant rearrangement. These results are consistent with a double recombination event (transplacement) between the transforming DNA and the host genome (Fig. 3).
Example 6
An AUGl strain of P. methanolica is grown in high-density fermentation conditions. The fermentation vessel is charged with mineral salts by the addition of 57.8 g (NH ) S04, 46.6 g KCl, 30.8 g MgS04-7H20, 8.6 g CaS0 -2H20, 2.0 g NaCl, and 10 ml antifoam (PPG). H20 is added to bring the volume to 2.5 L. and the solution is autoclaved 40 minutes. After cooling. 350 ml of 50% glucose. 250 ml 10 X trace elements (Table 4), 210 ml of 30% NaPhosphate, 25 ml 200 μg/ml biotin, and 250 ml cell inoculum are added. Cells are batch-fed glucose or glucose/methanol in three phases. In phase 1, the cells receive 0.4%/L/hour glucose (w/v final fermentation volume) for 25 hours using 750 g glucose, 1 10 g (NH4)2S04, and 278 ml 10 X trace elements per 1.5 liter. The cells are then given a transition feed of 0.2% glucose, 0.2% methanol/L/hour for 5 hours. The final glucose-supplemented methanol feed contains 0.1 % glucose, 0.4% methanol L/hr for 25 hours. Final biomass is about 300 g/L cell paste. Example 7
For fermentation of a P. methanolica auglΔ strain, the fermentation vessel is initially charged with mineral salts, glucose, phosphate, trace elements and biotin as disclosed in Example 6. 250 ml of cell inoculum is added. A glucose feed is prepared using 600 g glucose, 108 g (NH4) S04, and 273 ml 10 X trace elements per 1.2 liter. The cells are batch-fed in three phases. In the first phase, the cells receive glucose for 12 to 25 hours at 0.4%/L/hour. The cells are then induced with a bolus addition of 1% methanol by weight and transitioned to methanol utilization with a mixed 0.2% glucose/0.1% methanol feed for 10 hours. In the third phase, a mixed feed of 0.2%) glucose, 0.2%) methanol is delivered for 15 hours.
Example 8
P. methanolica cells in which the A UGl gene had been disrupted by insertion of a GAD65 expression construct retained the ability to grow on methanol. indicating that a second alcohol oxidase gene was present. The second gene, designated AUG2, was identified by PCR. Sequence analysis of the 5' coding region of the gene showed that the N-terminus of the encoded protein was similar to those of known alcohol oxidase genes.
Strain MC GAD8, a transformant that grew very poorly on minimal methanol broth, was used as a source for cloning the A UG2 gene. Genomic DNA was prepared from MC GAD8 and amplified with sense and antisense PCR primers specific for the AUGl open reading frame (8784, SEQ ID NO:5; 8787, SEQ ID NO:6). A product identical in size to the AUGl product but showing very low intensity on an analytical gel was obtained.
The putative A UG2 PCR product was digested with a battery of restriction enzymes. Partial digestion by Eco RI and Pvu I, and the presence of several Bgl II sites suggested that the DNA was contaminated with small amounts of AUGl. To remove the contaminating AUGl DNA, the PCR mixture was cut with Eco RI and gel purified. Since the MC GAD 8 product did not appear to have an Eco RI site, it was unaffected. The resulting gel-purified DNA was reamplified and again analyzed by restriction digestion. The DNA gave a different restriction map from that of the AUGl PCR product.
Southern blot analysis was performed on genomic DNA from MC GAD8 and wild- type cells using either AUGl or AUG2 open reading frame PCR fragments as probes. The AUG2 probe hybridized at low stringency to the AUGl locus and at both low and high stringency to a second locus. The A UGl probe bound to both loci at low stringency, but bound predominantly to the AUGl locus at high stringency. These data indicated that the new PCR product from MC GAD8 was similar to but distinct from AUGl. Sequence analysis showed an 83% identity between A UGl and A UG2 gene products.
To clone the A UG2 genomic locus. PCR primers were designed from the original AUG2 PCR fragment. Primers 9885 (SEQ ID NO:7) and 9883 (SEQ ID NO:8) were used to screen a P. methanolica genomic library. A positive clone bank pool was then probed with the original MC GAD8 PCR product. Cells were plated on 10 plates at about 5000 colonies/plate and grown overnight, then the plates were overlayed with filter discs (Hybond-N. Amersham Corp., Arlington Heights. IL). Colonies were denatured, neutralized, and UV cross-linked. Bacterial debris was washed from the filters with 5X SSC. and the filters were again cross-linked. Blots were pre- hybridized in pairs at 42°C for 1 hour in 25 ml hybridization buffer. Approximately 250 ng of probe was then added to each pair of filters. Hybridization was conducted at 42°C for four hours.
The blots were then washed in 500 ml of 0.1 X SSC, 6M urea. 0.4% SDS at 42°C for 10 minutes, four times. The blots were then neutralized with 500 ml of 2 X SSC at room temperature for 5 minutes, two rinses. The blots were then immersed in 100 ml development reagent (ECL,
Amersham Corp.).
Positive colonies were picked and amplified using PCR primers 9885 (SEQ ID
NO:7) and 9883 (SEQ ID NO:8) to confirm their identity. Positive pools were streaked on plates, and single colonies were rescreened by PCR. One colony was selected for further analysis
(restriction mapping and sequencing). A partial sequence of the A UG2 gene is shown in SEQ ID
NO:9. As shown in SEQ ID NO:9, the AUG2 sequence begins at the Hindlll site a nucleotide 91.
Nucleotides upstream from this position are vector sequence. The coding sequence begins at nucleotide 170. Disruption of the AUG2 gene had little effect on cell growth on methanol. Cells lacking both functional AUGl and AUG2 gene products did not grow on methanol. Subsequent analysis showed that the A UGl gene product is the only detectable alcohol oxidase in cells grown in a fermentor.
From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(l) APPLICANT: ZymoGenetics, Inc.
1201 Eastlake Avenue East Seattle, Washington 98102 United States of America di) TITLE OF INVENTION: PREPARATION OF PICHIA METHANOLICA AUXOTROPHIC MUTANTS
(ni) NUMBER OF SEQUENCES: 9
(ιv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: ZymoGenetics, Inc.
(B) STREET: 1201 Eastlake Avenue East
(C) CITY: Seattle
(D) STATE: WA
(E) COUNTRY: USA
(F) ZIP: 98102
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentin Release #1.0, Version #1.25
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(vili) ATTORNEY/AGENT INFORMATION:
(A) NAME: Parker, Gary E
(B) REGISTRATION NUMBER: 31-648
(C) REFERENCE/DOCKET NUMBER: 96-17
(lx) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 206-442-6673
(B) TELEFAX: 206-442-6678
(2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3077 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
( i i ) MOLECULE TYPE : Genomi c DNA ( i i i ) HYPOTHETICAL : NO ( i v ) ANTISENSE : NO ( v ) FRAGMENT TYPE : ( vi ) ORIGINAL SOURCE :
(xi ) SEQUENCE DESCRI PTION : SEQ ID N0 : 1 :
CAGCTGCTCT GCTCCπGAT TCGTAAπAA TGπATCCπ TTACπTGAA CTCπGTCGG 60
TCCCCAACAG GGAπCCAAT CGGTGCTCAG CGGGATπCC CATGAGGπT TTGACAACπ 120
TAπGATGCT GCAAAAACπ πTTAGCCGG GπTAAGTAA CTGGGCAATA TπCCAAAGG . 180
CTGTGGGCGT TCCACACTCC πGCTTπCA TAATCTCTGT GTATTGTTπ AπCGCAπT 240
TGAπcTcπ AπACCAGπ ATGTAGAAAG ATCGGCAAAC AAAATATCAA cTTπATcπ 300
GAACGCTGAC CCACGGπTC AAATAACTAT CAGAACTCTA TAGCTATAGG GGAAGTπAC 360
TGCπGCπA AAGCGGCTAA AAAGTGTπG GCAAATTAAA AAAGCTGTGA CAAGTAGGAA 420
CTCCTGTAAA GGGCCGATTC GAC.πCGAAA GAGCCTAAAA ACAGTGACTA TTGGTGACGG 480
AAAAπGCTA AAGGAGTACT AGGGCTGTAG TAATAAATAA TGGAACAGTG GTACAACAAT 540
AAAAGAATGA CGCTGTATGT CGTAGCCTGC ACGAGTAGCT CAGTGGTAGA GCAGCAGAπ 600
GCAAATCTGT TGGTCACCGG TTCGATCCGG TCTCGGGCπ TTITTCGATA 660
πTGCGGGTA GGAAGCAAGG TCTAGTTTTC GTCGπTCGG ATGGπTACG AAAGTATCAG 720
CCATGAGTGT πCCCTCTGG CTACCTAATA TAπTAπGA TCGGTCTCTC ATGTGAATGT 780
πcπTCCAA GπCGGCπT CAGCTCGTAA ATGTGCAAGA AATATπGAC TCCAGCGACC 840
πTCAGAGTC AAAπAATπ TCGCTAACAA πTGTGTTπ TCTGGAGAAA CCTAAAGAπ 900 TAACTGATAA GTCGAATCAA CATCπTAAA TCCTπAGTT AAGATCTCTG CAGCGGCCAG 960
TAπAACCAA TAGCATAπC ACAGGCATCA CATCGGAACA πCAGAATGG ACTCGCAAAC 1020
TGTCGGGATT πAGGTGGTG GCCAACπGG TCGTATGATC GπGAAGCTG CACACAGAπ 1080
GAATATCAAA ACTGTGAπC TCGAAAATGG AGACCAGGCT CCAGCAAAGC AAATCAACGC 1140
πTAGATGAC CATAπGACG GCTCAπCAA TGATCCAAAA GCAAπGCCG AAπGGCTGC 1200
CAAGTGTGAT GTπTAACCG πGAGAπGA ACATGπGAC ACTGATGCGT TGGπGAAGT 1260
TCAAAAGGCA ACTGGCATCA AAATCπCCC ATCACCAGAA ACTATTTCAT TGATCAAAGA 1320
TAAATACπG CAAAAAGAGC AπTGATTAA GAATGGCAπ GCTGπGCCG AATCπGTAG 1380
TGπGAAAGT AGCGCAGCAT CTπAGAAGA AGTTGGTGCC AAATACGGCT TCCCATACAT 1440
GCTAAAATCT AGAACAATGG CCTATGACGG AAGAGGTAAT TπGπGTCA AAGACAAGTC 1500
ATATATACCT GAAGCπTGA AAGTπTAGA TGACAGGCCG πATACGCCG AGAAATGGGC 1560
TCCATπTCA AAGGAGπAG CTGπATGGT TGTGAGATCA ATCGATGGCC AAGπTAπC 1620
CTACCCAACT GπGAAACCA TCCACCAAAA CAACATCTGT CACACTGTCT TTGCTCCAGC 1680
TAGAGπAAC GATACTGTCC AAAAGAAGGC CCAAATπTG GCTGACAACG CTGTCAAATC 1740 πTCCCAGGT GCTGGTATCT πGGTGπGA AATGππTA πACAAAATG GTGACπAπ 1800
AGTCAACGAA AπGCCCCAA GACCTCACAA TTCTGGTCAC TATACCATCG ACGCπGTGT 1860
CACCTCGCAA TπGAAGCTC ATGπAGGGC CAπACTGGT CTACCCATGC CGAAGAACπ 1920
CACπGπTG TCGACTCCAT CTACCCAAGC TATTATGπG AACGTπTAG GTGGCGATGA 1980
GCAAAACGGT GAGπCAAGA TGTGTAAAAG AGCACTAGAA ACTCCTCATG CπCTGπTA 2040
CπATACGGT AAGACTACAA GACCAGGCAG AAAAATGGGT CACAπAATA TAGπTCTCA 2100
ATCAATGACT GACTGTGAGC GTAGAπACA πACATAGAA GGTACGACTA ACAGCATCCC 2160
TCTCGAAGAA CAGTACACTA CAGAπCCAT TCCGGGCACT TCAAGCAAGC CAπAGTCGG 2220 TGTCATCATG GGπCCGAπ CGGACCTACC AGTCATGTCT CTAGGπGTA ATATAπGAA 2280
GCAAπTAAC GπCCAπTG AAGTCACTAT CGTπCCGCT CATAGAACCC CACAAAGAAT 2340
GGCCAAGTAT GCCAπGATG CTCCAAAGAG AGGGTTGAAG TGCATCAπG CTGGTGCTGG 2400
TGGTGCCGCT CATπACCGG GAATGGπGC GGCGATGACG CCGCTGCCTG πAπGGTGT 2460
CCCTGπAAA GGCTCTACπ TGGATGGTGT TGATTCACTA CACTCCATCG πCAAATGCC 2520
AAGAGGTAπ CCTGπGCTA CTGTGGCTAT TAACAATGCT ACTAACGCTG CCπGCTAGC 2580
TATCACAATC πAGGTGCCG GCGATCCAAA TACπGTCTG CAATGGAAGT πATATGAAC 2640
AATATGGAAA ATGAAGππ GGGCAAGGCT GAAAAATTGG AAAATGGTGG ATATGAAGAA 2700
TACπGAGTA CATACAAGAA GTAGAACCTT πATATTTGA TATAGTACπ ACTCAAAGTC 2760 πAAπGπC TAACTGπAA πTCTGCπT GCATTTCTGA AMGTπAAG ACAAGAAATC 2820 πGAAAπTC TAGπGCTCG TAAGAGGAAA CπGCATTCA AATAACAπA ACAATAAATG 2880
ACAATAATAT AπAπTCAA CACTGCTATA TGGTAGTπT ATAGGπTGG TTAGGA1TTG 2940
AGATAπGCT AGCGCπATC AπATCCTTA AπGTTCATC GACGCAAATC GACGCATπC 3000
CACAAAAAπ πCCGAACCT GTππCACT TCTCCAGATC πGGπTAGT ATAGCTTTTG 3060
ACACCTAATA CCTGCAG 3077
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3386 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Genomic DNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
GAATTCCTGC AGCCCGGGGG ATCGGGTAGT GGAATGCACG GπATACCCA CTCCAAATAA 60
AAGTGTAGTA GCCGGACTGA AAGGTπTAG GAGTCTGTπ GπTGπCAT GTGCATCAπ 120
CCCTAATCTG TTAACAGTCT CGGAGTATAC AAAAAAGTAA GTCAAATATC AAGGTGGCCG 180
GGGGCAGCAT CGAGACTCGA GATGGTACAT ACπAAAAGC TGCCATAπG AGGAACπCA 240
AAGπTTATC TGTπTTAGA AπAAAAGAC GAπGπGTA ACAAAACGπ GTGCCTACAT 300
AAACTCAAAT TAATGGAAAT AGCCTGTTTT GAAAAATACA CCπcπAAG TACTGACAAA 360
GπTTGπAA ATGACTATCG AACAAGCCAT GAAATAGCAC ATTTCTGCCA GTCACTπTA 420
ACACπiCCT GCπGCTGGT TGACTCTCCT CATACAAACA CCCAAAAGGG AAACTπCAG 480
TGTGGGGACA CπGACATCT CACATGCACC CCAGAπAAT πCCCCAGAC GATGCGGAGA 540
CAAGACAAAA CAACCCTπG TCCTGCTCπ πcπTCTCA CACCGCGTGG GTGTGTGCGC ' 600
AGGCAGGCAG GCAGGCAGCG GGCTGCCTGC CATCTCTAAT CGCTGCTCCT CCCCCCTGGC 660
πCAAATAAC AGCCTGCTGC TATCTGTGAC CAGAπGGGA CACCCCCCTC CCCTCCGAAT 720
GATCCATCAC CTπTGTCGT ACTCCGACAA TGATCCπCC CTGTCATCπ CTGGCAATCA 780
GCTCCπCAA TAATTAAATC AAATAAGCAT AAATAGTAAA ATCGCATACA AACGTCATGA 840
AAAGπTTAT CTCTATGGCC AACGGATAGT CTATCTGCπ AAπCCATCC ACTπGGGAA 900
CCGCTCTCTC πTACCCCAG AπCTCAAAG CTAATATCTG CCCCπGTCT AπGTCCπT 960
CTCCGTGTAC AAGCGGAGCT πTGCCTCCC ATCCTCπGC πTGTπCGG TTAI 11 III I 1020
πcππGAA ACTCπGGTC AAATCAAATC AAACAAAACC AAACCπCTA πCCATCAGA 1080
TCAACCπGT TCAACAπCT ATAAATCGAT ATAAATATAA CCπATCCCT CCCπGππ 1140
πACCAAπA ATCAATCπC AAAπTCAAA TATπTCTAC πGCπTAπ ACTCAGTAπ 1200
AACAπTGπ TAAACCAACT ATAACTπTA ACTGGCTπA GAAGπiTAT TTAACATCAG 1260 lTTCAAMTA CATCπTAπ TAπAACGAA ATCTπACGA ATTAACTCAA TCAAAACTπ 1320
TACGAAAAAA AAATCπACT AπAATπCT CAAAATGGCT ATTCCAGATG AATTTGATAT 1380
TAπGπGTC GGTGGTGGπ CCACCGGπG TGCTCTTGCT GGTAGAπAG GTAACπGGA 1440
CGAAAACGTC ACAGTTGCTT TAATCGAAGG TGGTGAAAAC AACATCAACA ACCCATGGGT 1500 πACπACCA GGTGTTTATC CAAGAAACAT GAGAπAGAC TCAAAGACTG CTACTππA 1560
CTCπCAAGA CCATCACCAC ACTTGAACGG TAGAAGAGCT AπGπCCAT GTGCTAACAT 1620
CπGGGTGGT GGπCTTCCA TCAACπcπ GATGTACACC AGAGCCTCTG CCTCCGAπA 1680
CGATGAπGG GAATCTGAAG GπGGACTAC CGATGAATTA πACCACTAA TGAAGAAGAT 1740
TGAAACπAT CAAAGACCAT GTAACAACAG AGAAπGCAC GGπTCGATG GTCCAAπAA 1800
GGπTCAπT GGTAACTATA CTTATCCAAA CGGTCAAGAT πCATTAGAG CTGCCGAATC 1860
TCAAGGTAπ CCAπTGπG ATGATGCTGA AGATπGAAA TGTTCCCACG GTGCTGAGCA 1920
CTGGπGAAG TGGATCAACA GAGACπAGG TAGAAGATCC GAπCTGCTC ATGCπACAT 1980
TCACCCAACC ATGAGAAACA AGCAAAACTT GπcπGATT ACTTCCACCA AGTGTGAAAA 2040
GAπATCAπ GAAAACGGTG πGCTACTGG TGπAAGACT GTTCCAATGA AGCCAACTGG 2100
πCTCCAAAG ACCCAAGπG CTAGAACTπ CAAGGCTAGA AAGCAAATTA TTGπTCπG 2160
TGGTACTATC TCATCACCAT TAGππGCA AAGATCTGGT ATCGGπCCG CTCACAAGπ 2220
GAGACAAGπ GGTAπAAAC CAAπGπGA CπACCAGGT GπGGTATGA ACπCCAAGA 2280
TCACTACTGT πcπCACTC CATACCATGT CAAGCCAGAT ACTCCATCAT TCGATGACπ 2340
TGπAGAGGT GATAAAGCTG πCAAAAATC TGCTπCGAC CAATGGTATG CTAACAAGGA 2400
TGGTCCAπA ACCACTAATG GTATTGAGGC AGGTGπAAG AπAGACCAA CTGAAGAAGA 2460
AπAGCCACT GCTGATGACG AAπCAGAGC TGCπATGAT GACTACTπG GTAACAAGCC 2520
AGATAAGCCA πAATGCACT ACTCTCTAAT πCTGGTπC TTTGGTGACC ACACCAAGAT 2580 TCCAAACGGT AAGTACATGT GCATGTTCCA CπcπGGAA TATCCAπCT CCAGAGGTπ 2640
CGπCACGTT GπTCTCCAA ACCCATACGA TGCTCCTGAC 1TTGATCCAG GTTTCATGAA 2700
CGATCCAAGA GATATGTGGC CAATGGTTTG GTCπACAAG AAGTCCAGAG AAACTGCCAG 2760
AAGAATGGAC TGTπTGCCG GTGAAGTTAC πCTCACCAC CCACACTACC CATACGACTC 2820
ACCAGCCAGA GCTGCTGACA TGGACπGGA AACTACTAAA GCπATGCTG GTCCAGACCA 2880
CTπACTGCT AACπGTACC ACGGπCATG GACTGπCCA ATTGAAAAGC CAACTCCAAA 2940
GAACGCTGCT CACGπACπ CTAACCAAGT TGAAAAACAT CGTGACATCG AATACACCAA 3000
GGAGGATGAT GCTGCTATCG AAGAπACAT CAGAGAACAC ACTGAAACCA CATGGCAπG 3060
TCπGGTACT TGπCAATGG CTCCAAGAGA AGGπCTAAG GTTGTCCCAA CTGGTGGTGT 3120
TGπGACTCC AGAπAAACG πTACGGTGT TGAAAAGπG AAGGπGCTG ATTTATCAAT 3180 πGCCCAGAT AATGπGGπ GTAACACπA CTCTACTGCT πGπAATCG GTGAAAAGGC 3240
πCTACCπA GπGCTGAAG ACπGGGCTA CTCTGGTGAT GCπTGAAGA TGACTGπCC 3300
AAACπCAAA πGGGTACπ ATGAAGAAGC TGGTCTAGCT AGATTCTAGG GCTGCCTGπ 3360
TGGATATTπ TATAATππ GAGAGT 3386
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
TGATCACCTA GGACTAGTGA CAAGTAGGAA CTCCTGTA 38 (2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:4: CAGCTGCCTA GGACTAGTπ CCTCπACGA GCAACTAGA 39
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:5: TGGπGAAGT GGATCAA 17
(2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:
GTGTGGTCAC CGAAGAA 17
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (vii) IMMEDIATE SOURCE: (B) CLONE: ZC9885
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
GπGπccπ ccA CCAπ GAAC 24
(2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(vii) IMMEDIATE SOURCE: (B) CLONE: ZC9883
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:
AAAGTAAGAA GCGTAGCCTA GπG 24
(2) INFORMATION FOR SEQ ID N0:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 329 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:9:
GACCATGAπ ACGCCAAGCG CGCAAπAAC CCTCACTAAA GGGAACAAAA GCTGGGTACC 60
GGGCCCCCCC TCGAGGTCGA CGGTATCGAT AAGCπTAπ ATAACAπAA TATACTATTT 120
TATAACAGGA πGAAAAπA TATTTATCTA TCTAAAACTA AAAπCAAAA TGGCTAπCC 180 TGAAGAAπC GATATCAπG πGTCGGTGG TGGπCTGCC GGCTGTCCTA CTGCTGGTAG 240
AπGGCTAAC πAGACCCAA AπTAACTGT TGCTπAATC GAAGCTGGTG AAAACAACAT 300
TAACAACCCA TGGGTCTACT TACCAGGCG 329

Claims

Claims What is claimed is:
1. A method for preparing Pichia methanolica cells having an auxotrophic mutation comprising:
(a) exposing P. methanolica cells to mutagenizing conditions;
(b) culturing the cells from step (a) in a rich medium to allow mutations to become established and replicated in at least a portion of said cells;
(c) culturing the cells from step (b) in a culture medium deficient in assimilable nitrogen to deplete cellular nitrogen stores;
(d) culturing the cells from step (c) in a defined culture medium comprising an inorganic nitrogen source and an amount of nystatin sufficient to kill growing P. methanolica cells to select for cells having a deficiency in a nutritional gene; and
(e) culturing the selected cells from step (d) in a rich culture medium.
2. A method according to claim 1 wherein the selected cells from step (e) are replica plated to a defined medium and cultured to confirm the presence of an auxotrophic mutation.
3. A method according to claim 1 wherein the selected cells are auxotrophic for adenine.
4. A method according to claim 3 wherein the selected cells are deficient in phosphoribosyl-5-aminoimidazole carboxylase.
5. A method according to claim 1 wherein the defined culture medium contains 2 mgZL nystatin.
6. A method according to claim 1 wherein the mutagenizing conditions comprise exposure to ultraviolet light.
7. A method according to claim 1 wherein the mutagenizing conditions comprise exposure to a chemical mutagen.
8. A method according to claim 1 wherein the inorganic nitrogen source comprises ammonium ions.
9. A method according to claim 8 wherein the inorganic nitrogen source ulfate.
PCT/US1997/012582 1996-07-17 1997-07-14 Preparation of pichia methanolica auxotrophic mutants WO1998002536A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP97936103A EP0946734B1 (en) 1996-07-17 1997-07-14 Preparation of pichia methanolica auxotrophic mutants
DE69735369T DE69735369T2 (en) 1996-07-17 1997-07-14 PREPARATION OF AUXOTROPHIC MUTANES FROM PICHIA METHANOLICA
JP50632398A JP2002514049A (en) 1996-07-17 1997-07-14 Production of auxotrophic mutants of Pichia methanolica
IL12807297A IL128072A0 (en) 1996-07-17 1997-07-14 Preparation of pichia methanolica auxotrophic mutants
CA002261020A CA2261020C (en) 1996-07-17 1997-07-14 Preparation of pichia methanolica auxotrophic mutants
AU38856/97A AU708572B2 (en) 1996-07-17 1997-07-14 Preparation of (pichia methanolica) auxotrophic mutants

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68350096A 1996-07-17 1996-07-17
US08/683,500 1996-07-17
US08/703,808 1996-08-26
US08/703,808 US5736383A (en) 1996-08-26 1996-08-26 Preparation of Pichia methanolica auxotrophic mutants

Publications (2)

Publication Number Publication Date
WO1998002536A2 true WO1998002536A2 (en) 1998-01-22
WO1998002536A3 WO1998002536A3 (en) 1998-02-26

Family

ID=27103122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/012582 WO1998002536A2 (en) 1996-07-17 1997-07-14 Preparation of pichia methanolica auxotrophic mutants

Country Status (6)

Country Link
JP (1) JP2002514049A (en)
CN (1) CN1238806A (en)
AU (1) AU708572B2 (en)
CA (1) CA2261020C (en)
IL (1) IL128072A0 (en)
WO (1) WO1998002536A2 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040716A2 (en) 1999-01-07 2000-07-13 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
WO2007038703A2 (en) 2005-09-28 2007-04-05 Zymogenetics, Inc Il-17a and il-17f antagonists and methods of using the same
CN100347287C (en) * 2004-09-30 2007-11-07 汪和睦 Recombinated multi shape ttansenula yeast, its structural method and application
EP2042196A2 (en) 2001-10-10 2009-04-01 Neose Technologies, Inc. Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP2105446A2 (en) 1998-09-23 2009-09-30 ZymoGenetics, Inc. Cytokine receptor zalpha11
EP2116259A1 (en) 2001-05-24 2009-11-11 ZymoGenetics, Inc. TACI-immunoglobulin fusion proteins
EP2130919A1 (en) 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21 antagonists
EP2163635A1 (en) 2004-08-02 2010-03-17 BASF Plant Science GmbH Method for isolation of transcription termination sequences
EP2192132A2 (en) 2005-02-08 2010-06-02 ZymoGenetics, Inc. Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP2194130A1 (en) 1999-12-23 2010-06-09 ZymoGenetics, L.L.C. Cytokine ZCYTO18
WO2010069913A1 (en) 2008-12-16 2010-06-24 Novartis Ag Yeast display systems
US7772365B2 (en) 1999-01-07 2010-08-10 Zymogenetics, Inc. Soluble receptor BR43x2
EP2230299A1 (en) 2002-01-18 2010-09-22 ZymoGenetics, Inc. Novel cytokine ZCYTOR17 ligand
EP2241623A2 (en) 1999-07-07 2010-10-20 ZymoGenetics, Inc. Monoclonal antibody against a human cytokine receptor
US7842292B2 (en) 2005-08-09 2010-11-30 Ares Trading S.A. Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
EP2258725A2 (en) 2000-06-26 2010-12-08 ZymoGenetics, L.L.C. Cytokine receptor zcytor17
EP2295577A2 (en) 1999-03-09 2011-03-16 ZymoGenetics, Inc. Human cytokine as ligand of the z-alpha receptor and uses thereof
EP2295455A1 (en) 2002-04-19 2011-03-16 ZymoGenetics, L.L.C. Cytokine receptor
EP2298354A2 (en) 2001-10-10 2011-03-23 BioGeneriX AG Remodelling and glycoconjugation of interferon-beta
EP2301971A1 (en) 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antibodies that bind both BCMA and TACI
EP2338910A1 (en) 2002-01-18 2011-06-29 ZymoGenetics, Inc. Cytokine receptor Zcytor17 multimers
EP2397493A1 (en) 2005-05-12 2011-12-21 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
EP2602263A2 (en) 2007-11-21 2013-06-12 Roskilde Universitet Polypeptides comprising an ice-binding activity
WO2013116771A1 (en) 2012-02-01 2013-08-08 Synthetic Genomics, Inc. Materials and methods for the synthesis of error-minimized nucleic acid molecules
US8653020B2 (en) 2008-01-25 2014-02-18 Aarhus Universitet Selective exosite inhibition of PAPP-A activity against IGFBP-4
US8784812B2 (en) 2006-05-15 2014-07-22 Zymogenetics, Inc. Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
WO2014202089A2 (en) 2013-06-18 2014-12-24 Roskilde Universitet Variants of anti-freeze polypeptides
CN111157680A (en) * 2019-12-31 2020-05-15 北京辰安科技股份有限公司 Indoor volatile substance leakage tracing method and device

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116064597B (en) * 2023-01-17 2024-04-26 北京大学 Directed evolution and darwinian adaptation in mammalian cells by autonomous replication of RNA

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017450A2 (en) * 1995-11-09 1997-05-15 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in pichia methanolica

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017450A2 (en) * 1995-11-09 1997-05-15 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in pichia methanolica
WO1997017451A2 (en) * 1995-11-09 1997-05-15 Zymogenetics, Inc. Production of gad65 in methylotrophic yeast

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. BA64, Philadelphia, PA, US; abstract no. 50226, TOLSTORUKOV I I ET AL: "HYBRIDIZATION AND GENETIC ANALYSIS OF THE METHANOL UTILIZING YEAST PICHIA-PINUS." XP002051202 & GENETIKA 13 (2). 1977 322-329. CODEN: GNKAA5 ISSN: 0016-6758, *
BIOLOGICAL ABSTRACTS, vol. BA85, Philadelphia, PA, US; abstract no. 37426, TOLSTORUKOV I I ET AL: "GENETIC CONTROL OF PURINE BIOSYNTHESIS IN THE YEAST PICHIA PINUS I. GENUS CONTROLLING THE VI AND VII STEPS." XP002051203 & GENETIKA 23 (8). 1987. 1399-1406. CODEN: GNKAA5 ISSN: 0016-6758, *
LAWRENCE C.W.: "Classical mutagenesis techniques" METHODS IN ENZYMOLOGY, vol. 194, 1991, pages 273-281, XP002050288 cited in the application *
SNOW R.: "An enrichment method for auxotrophic yeast mutants using the antibiotic 'nystatin'" NATURE, vol. 211, 9 July 1966, pages 206-207, XP002050287 cited in the application *
TOLSTORUKOV I I ET AL: "MUTANTS OF THE METHYLOTROPHIC YEAST PICHIA PINUS DEFECTIVE IN C-2 METABOLISM." YEAST 5 (3). 1989. 179-186. CODEN: YESTE3 ISSN: 0749-503X, XP002051201 *

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2105446A2 (en) 1998-09-23 2009-09-30 ZymoGenetics, Inc. Cytokine receptor zalpha11
WO2000040716A2 (en) 1999-01-07 2000-07-13 Zymogenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
EP2256199A1 (en) 1999-01-07 2010-12-01 ZymoGenetics, Inc. Therapeutic uses of BR43X2 soluble receptors
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US7772365B2 (en) 1999-01-07 2010-08-10 Zymogenetics, Inc. Soluble receptor BR43x2
EP2295577A2 (en) 1999-03-09 2011-03-16 ZymoGenetics, Inc. Human cytokine as ligand of the z-alpha receptor and uses thereof
EP2241623A2 (en) 1999-07-07 2010-10-20 ZymoGenetics, Inc. Monoclonal antibody against a human cytokine receptor
EP2194130A1 (en) 1999-12-23 2010-06-09 ZymoGenetics, L.L.C. Cytokine ZCYTO18
EP2258725A2 (en) 2000-06-26 2010-12-08 ZymoGenetics, L.L.C. Cytokine receptor zcytor17
EP2301971A1 (en) 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antibodies that bind both BCMA and TACI
EP2116259A1 (en) 2001-05-24 2009-11-11 ZymoGenetics, Inc. TACI-immunoglobulin fusion proteins
EP2279753A2 (en) 2001-10-10 2011-02-02 Novo Nordisk A/S Remodeling and glycoconjugation of peptides
EP2298354A2 (en) 2001-10-10 2011-03-23 BioGeneriX AG Remodelling and glycoconjugation of interferon-beta
EP2305313A2 (en) 2001-10-10 2011-04-06 BioGeneriX AG Remodelling and glycoconjugation of interferon-alpha (IFNa)
EP2322229A2 (en) 2001-10-10 2011-05-18 Novo Nordisk A/S Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
EP2080525A1 (en) 2001-10-10 2009-07-22 BioGeneriX AG Remodeling and Glycoconjugation of Peptides
EP2279755A2 (en) 2001-10-10 2011-02-02 BioGeneriX AG Remodelling and glycoconjugation of Fibroblast Growth Factor (FGF)
EP2305311A2 (en) 2001-10-10 2011-04-06 BioGeneriX AG Glycoconjugation of peptides
EP2042196A2 (en) 2001-10-10 2009-04-01 Neose Technologies, Inc. Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
EP2279754A2 (en) 2001-10-10 2011-02-02 BioGeneriX AG Remodelling and glycoconjugation of human growth hormone (hGH)
EP2305314A2 (en) 2001-10-10 2011-04-06 BioGeneriX AG Remodelling and glycoconjugation of antibodies
EP2305312A2 (en) 2001-10-10 2011-04-06 BioGeneriX AG Remodelling and glycoconjugation of follicle-stimulating hormone (FSH)
EP2130919A1 (en) 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21 antagonists
EP2230299A1 (en) 2002-01-18 2010-09-22 ZymoGenetics, Inc. Novel cytokine ZCYTOR17 ligand
EP2338910A1 (en) 2002-01-18 2011-06-29 ZymoGenetics, Inc. Cytokine receptor Zcytor17 multimers
EP2840089A1 (en) 2002-01-18 2015-02-25 ZymoGenetics, Inc. Cytokine receptor zcytor17 multimers
EP2295455A1 (en) 2002-04-19 2011-03-16 ZymoGenetics, L.L.C. Cytokine receptor
EP2338333A2 (en) 2003-04-09 2011-06-29 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP2166104A1 (en) 2004-08-02 2010-03-24 BASF Plant Science GmbH Method for isolation of transcription termination sequences
EP2166103A1 (en) 2004-08-02 2010-03-24 BASF Plant Science GmbH Method for isolation of transcription termination sequences
EP2163635A1 (en) 2004-08-02 2010-03-17 BASF Plant Science GmbH Method for isolation of transcription termination sequences
CN100347287C (en) * 2004-09-30 2007-11-07 汪和睦 Recombinated multi shape ttansenula yeast, its structural method and application
EP2192132A2 (en) 2005-02-08 2010-06-02 ZymoGenetics, Inc. Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP3683230A1 (en) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
EP2397493A1 (en) 2005-05-12 2011-12-21 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
EP2399932A1 (en) 2005-05-12 2011-12-28 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
EP3214095A1 (en) 2005-05-12 2017-09-06 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
US7842292B2 (en) 2005-08-09 2010-11-30 Ares Trading S.A. Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
WO2007038703A2 (en) 2005-09-28 2007-04-05 Zymogenetics, Inc Il-17a and il-17f antagonists and methods of using the same
US8784812B2 (en) 2006-05-15 2014-07-22 Zymogenetics, Inc. Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
EP2602263A2 (en) 2007-11-21 2013-06-12 Roskilde Universitet Polypeptides comprising an ice-binding activity
US8653020B2 (en) 2008-01-25 2014-02-18 Aarhus Universitet Selective exosite inhibition of PAPP-A activity against IGFBP-4
WO2010069913A1 (en) 2008-12-16 2010-06-24 Novartis Ag Yeast display systems
WO2013116771A1 (en) 2012-02-01 2013-08-08 Synthetic Genomics, Inc. Materials and methods for the synthesis of error-minimized nucleic acid molecules
EP3597764A2 (en) 2012-02-01 2020-01-22 SGI-DNA, Inc. Material and methods for the synthesis of error-minimized nucleic acid molecules
WO2014202089A2 (en) 2013-06-18 2014-12-24 Roskilde Universitet Variants of anti-freeze polypeptides
CN111157680A (en) * 2019-12-31 2020-05-15 北京辰安科技股份有限公司 Indoor volatile substance leakage tracing method and device

Also Published As

Publication number Publication date
CA2261020C (en) 2004-06-08
AU708572B2 (en) 1999-08-05
CA2261020A1 (en) 1998-01-22
AU3885697A (en) 1998-02-09
WO1998002536A3 (en) 1998-02-26
IL128072A0 (en) 1999-11-30
JP2002514049A (en) 2002-05-14
CN1238806A (en) 1999-12-15

Similar Documents

Publication Publication Date Title
US5736383A (en) Preparation of Pichia methanolica auxotrophic mutants
US5888768A (en) Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5716808A (en) Genetic engineering of pichia methanolica
CA2237120C (en) Compositions and methods for producing heterologous polypeptides in pichia methanolica
AU708572B2 (en) Preparation of (pichia methanolica) auxotrophic mutants
AU718510B2 (en) Transformation of pichia methanolica
US5854039A (en) Transformation of pichia methanolica
US6153424A (en) Protease-deficient strains of Pichia methanolica
US6001597A (en) Compositions and methods for producing heterologous polypeptides in Pichia methanolica
EP0946734B1 (en) Preparation of pichia methanolica auxotrophic mutants
WO1999014347A1 (en) PROTEASE-DEFICIENT STRAINS OF $i(PICHIA METHANOLICA)
EP1015577B1 (en) Chromosomal mutagenesis in pichia methanolica
BR112013000219A2 (en) method for the production of a recombinant poi a high production cell line and a high production cell culture, methods to increase the yield and prolong the production phase of a recombinant poi
US6183953B1 (en) Chromosomal mutagenesis in Pichia methanolica
US6613547B1 (en) Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase 1 promoter and terminator
EP0920525A1 (en) TRANSFORMATION OF $i(PICHIA METHANOLICA)
US6348331B1 (en) Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase 2 promoter
MXPA00002567A (en) Chromosomal mutagenesis in pichia methanolica
DE69735369T2 (en) PREPARATION OF AUXOTROPHIC MUTANES FROM PICHIA METHANOLICA
EP1210412A1 (en) Pichia methanolica glyceraldehyde-3-phosphate dehydrogenase 2 promoter and terminator

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97197503.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2261020

Country of ref document: CA

Ref document number: 2261020

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997936103

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997936103

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997936103

Country of ref document: EP